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Abstract
The present study examined whether duration of oral contraceptive (OC) 
use could account for the inconsistent findings of previous studies on the 
relationship between affect and OC use. This study was the first to examine 
positive affect variability and to directly compare early, late, and never users of 
OCs, The Positive and Negative Affect Schedule (PANAS) and the Menstrual 
Distress Questionnaire (MDQ) were filled out daily for 35 days by 96  female 
university students (17 first-time OC users, 34 long-time users, and 45 never- 
users). Despite predictions to the contrary, no group differences were found 
for negative affect, positive affect, or affect variability. However, exploratory 
analyses suggested that OC type (monophasic vs. triphasic) has a differential 
effect on positive affect variability across the menstrual cycle for first-time and 
long-time OC users. Neither somatic symptoms or somatic symptom variability 
could entirely account for these differences. The overall findings suggest that 
while no common change in affect or affect variability occurs in all women 
taking OCs, OC type (a pharmacological factor), duration of use, and individual 
difference variables may warrant further exploration as mediating variables in 
OC-related affect changes. Finally, while the main results found no support for 
the role of the “survivor effect" as an artifactual confound, the results of an 
exploratory comparison suggest that for specific groups of women, it may be 
a confound.
i i
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Effects of Oral Contraceptives on Daily Self-Ratings 
of Positive and Negative Affect 
The oral contraceptive (OC) pill is the most popular form of birth control 
in North America (Ortho, 1991) and has been used by an estimated 200 million 
women worldwide (Goldzieher, 1994). The popularity of this form of hormonal 
contraception among women necessitates an awareness of all side effects 
(positive and negative) and an awareness of the predisposing conditions that 
may make some women more prone to these side effects. Mood change 
remains one of the controversial side effects of OC use despite a great deal of 
research. Change in mood, specifically depression, is one of the most common 
reasons given for discontinuing OC use and there are, unquestionably, some 
women in whom OCs produce unacceptable changes in affect (Goldzieher,
1994). Research on mood side effects of “the pill” is important whether the 
mood change is positive or negative, and whether the cause is pharmacological 
or psychological. Women need scientific assessments of benefits and risks in 
order to make an informed choice about what type of contraceptive method 
or what type of OC pill is the best for them.
Biochemical Theories: Hormones and Mood
The exact mechanism for a pharmacological effect of OCs on mood is 
not yet known but there are a number of plausible hypotheses as to how the 
estrogen or progestogen in OCs could lead to positive or negative mood
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change. As reviewed by Delgado, Price, Heninger, and Chamey (1992), changes 
in the serotonergic system, noradrenaline system, and the dopaminergic 
system have all been associated with affective disorders and changes in mood. 
To simplify things, increases in serotonin, dopamine, and alphai-adrenoreceptor 
binding, and decreases in beta-adrenergic and alphaz receptor binding have 
been associated with mood improvements or manic symptoms. Decreases in 
both serotonin and dopamine have been associated with deterioration in mood 
or depressive symptoms. No clear consensus yet exists on which hormonal 
component of the OC acts on which neurotransmitter system or even whether 
increased or decreased levels of progesterone or estrogen are associated with 
mood improvement or deterioration. Researchers have, however, proposed a 
number of plausible mechanisms through which mood change associated with 
OC use could occur.
The majority of researchers in the area have hypothesized that changes 
in serotonin levels due to OCs result in mood change (e.g., Deijen, Duyn, Jansen,
& Klitsie, 1992; Patten & Love, 1993; Sheehan & Sheehan, 1976; Sherwin, 1996; 
Slap, 1981 ; Special Advisory Committee on Reproductive Physiology, 1994).
The estrogen component of the OC may lead to mood changes by acting on 
the serotonergic system (e.g., Deijen et al., 1992; Patten & Love, 1993;
Sheehan & Sheehan, 1976; Shenvin, 1996; Slap, 1981 ; Special Advisory 
Committee on Reproductive Physiology, 1994). Mood improvements following
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estrogen intake may occur through two pathways. First, an increased rate of 
monoamine oxidase degradation may lead to increased availability of 
tryptophan resulting in increases in serotonin (Sherwin, 19 96 ). Second, 
estrogen’s inhibition of the enzyme hydroxyindole-o-methyltransferase (HIOMT), 
which converts serotonin to melatonin in the pineal gland, may lead to increased 
serotonin levels (Slap, 1981). It has also been suggested that estrogen may 
lead to a deterioration in mood by causing a functional vitamin Bg deficiency, 
which alters tryptophan metabolism and decreases serotonin (Deijen et al.,
1992; Patten & Love, 1993; Sheehan & Sheehan, 1976; Special Advisory 
Committee on Reproductive Physiology, 1994).
Progesterone could also effect mood through the serotonergic system. 
One hypothesis is that progesterone leads to mood deterioration by increasing 
monoamine oxidase activity resulting in decreased concentrations of serotonin 
(Sheehan & Sheehan, 1976; Sherwin, 1996). Another possibility is that 
progesterone improves mood by increasing insulin levels resulting in a higher 
tryptophan to large neutral amino acid ratio, which leads to an increased 
concentration of serotonin (Tuiten et al., 1995).
The involvement of other neurotransmitters besides serotonin has been 
suggested. Moller (1981 ) hypothesized that mood deterioration in OC users is 
the result of a substrate-limited reduction in brain noradrenaline synthesis due 
to a decreased brain tyrosine concentration. Deijen et al. (1 9 9 2 ) suggested
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that the reduced concentration of noradrenalin in the hypothalamus following 
an OC induced vitamin Bg deficiency may account for OC-related mood 
deterioration. Finally, based on animal research, Roy-Byme, Rubinow, Gold, and 
Post ( 1984) hypothesized that estrogen may lead to mood improvements by 
decreasing the sensitivity of presynaptic dopamine autoreceptors. These 
hypotheses suggest that while the pharmacologic mechanism through which 
OCs act on mood is not known, plausible mechanisms exist by which both 
estrogen and progesterone can both lead to improvement and deterioration in 
mood.
Obviously increased doses of estrogen or progesterone cannot 
simultaneously cause negative and positive mood change in one women at one 
time. Other, as of yet unidentified, variables must mediate the direction of the 
mood change. Further research is needed to clarify the relationship between 
these two hormones and mood and to identify mediating variables.
Mood Versus Affect
Mood is a broad and complex area of research. The American 
Psychiatric Association (1994) compares mood and affect to climate and 
weather respectively. Mood is referred to as “a more pervasive and sustained 
emotional ‘climate’” while affect involves “more fluctuating changes in emotional 
‘weather’” (p. 763). Early research on the relationship between mood and oral 
contraceptive use took a categorical approach by focusing on the presence or
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absence of diagnosable mood disorders in women who use oral contraceptives 
(OC users). Most studies looked for increased incidence of clinical depression in 
OC users (e.g., Herzberg, Johnson, & Brown, 1970; Kutner & Brown, 1972; 
Vessey, McPhearson, & Yeates, 1985). Another approach involves viewing 
mood as a dimensional continuum and measuring the positive or negative mood 
change occurring during oral contraceptive use. The dimensional approach 
allows one to look at sub-clinical change and thus investigate changes in all 
women as opposed to only those who develop a mood disorder. It also allows 
for the measurement of both positive affect change and negative affect 
change. Positive affect reflects the extent to which a person avows a zest for 
life. Someone with high positive affect is characterized as attentive, interested, 
alert, and enthusiastic. Someone with low positive affect feels sleepy and tired. 
Negative affect reflects the extent to which a person conveys feeling distressed 
or unpleasantly aroused. A person with high negative affect feels downhearted, 
hostile, angry, fearful, and guilty, while someone with low negative affect is 
characterized as calm and content (Watson & Tellegen, 1985). The rationale 
for measuring negative and positive affect separately comes from recent 
studies, summarized by Watson and Tellegen, which have consistently found 
that positive and negative affect are the two dominant and relatively 
independent dimensions within affect (e.g., Diener & Emmons, 1985; Kercher, 
1992).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
6
Thus, a categorical approach to investigating mood change associated 
with OC use is concerned with the development of a diagnosable mood disorder 
while the dimensional approach looks at shorter-term changes in mood or levels 
of negative and/or positive affect,
Earlv Research: Oral Contraceptives and Mood
When looking at studies on the relationship between OC use and 
mood change, it is important to keep in mind that a major reduction of the 
estrogen dosage in oral contraceptives occurred in 1985. This means that 
most research done before 1985 is outdated since most studies involved oral 
contraceptives which contained higher dosages of estrogen than are used 
today.
The early research on mood change associated with oral contraceptive 
use has produced inconsistent findings. Most has involved cross-sectional, 
prospective, and randomized placebo designs which involve the assessment of 
mood one to three times over the course of several months. This differs from 
the more recent approach of using daily ratings of affect. Most early studies 
compared never-users, past-users, and present-users of oral contraceptives. 
The early studies usually either compared rates of depressive disorders 
between the two or three groups (e.g.. Royal College of General Practitioners,
1974) or compared scores on mood rating scales designed to measure 
general or average mood (e.g., Herzberg, Johnson, & Brown, 1970). Some
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researchers have found increased rates of depression in oral contraceptive 
users (e.g., Cullberg, 1972; Herzberg, Johnson, & Brown, 1970; Nilsson & 
Almgren, 1968). Others have found a decrease in depression rates (e.g., Deijen 
et al., 1992; Herzberg, Draper, Johnson, & Nicol, 1971), and some studies 
have not found any relationship between oral contraceptive use and incidence 
of depression (e.g., Fleming & Seager, 1978; Vessey et al., 1985). While many 
reviews of the early research in this area are incomplete, Cullberg (1972 ), Long 
and Kathol (1 9 9 3 ), and Slap (1 9 8 1 ) include most of the best-conducted 
studies.
A number of obvious methodological deficiencies may be responsible for 
the varied findings in the early studies. Many studies did not include an 
appropriate control group that would allow for a comparison of adverse mood 
changes between oral contraceptive users and non-users (e.g., Akerlund, Rode,
& Westergaard, 1983; Murawski, Sapir, Shulman, Ryan, & Sturgis, 1968;
Nilsson, Jacobson, & Ingemansson, 1967; Nilsson & Solvell, 1967; West, 1968). 
A number had a very small sample size (e.g.. Click, Hauptman, & Klein, 1970; 
Grounds, Davies, & Mowbray, 1970; Leeton, 1973; Marcotte, Kane, Obrist, & 
Upton, 1970; Silbergeld, Brast, & Noble, 1971; Worsley & Chang, 1978).
Lewis and Hoghughi (1 9 6 9 ) included a biased sample since the OC users were 
preselected for depression. Finally, many of the reports were case studies 
(e.g., Kane, 1968; Kane, Daly, Ewing, & Keeler, 1967) or retrospective studies




Another possible reason for the inconsistent results in the early literature 
may have involved the measurement methodology. Mood was usually 
measured or assessed one or two times over one to three months. Perhaps 
the mood changes associated with oral contraceptive use involve an increase 
or decrease in mood variability or changes at specific phases of the menstrual 
cycle. A sensitive measurement methodology may be needed to record subtle 
changes. Daily mood ratings, or more accurately, daily ratings of affect, may 
be a more sensitive indicator of differences between users and non-users of 
oral contraceptives.
The more recent shift has been to focus on differences in affect by 
having subjects fill out daily self-rating scales for 30 to 90 days (e.g. Almagor 
& Ben-Porath, 1991; Walker & Bancroft, 1990). Daily rating scales can be 
used to examine cyclical changes in affect across the menstrual cycle and 
general trends or differences in mood between the OC users and non-users. 
Thus, daily rating scales measure affect but the mean of 35 of these daily 
ratings of affect can give an indication of an individual’s mood.
Recent Research: Oral Contraceptives and Affect
A review of the literature found 17 published studies whose methodology 
involved both OC users and non-users rating their affect daily. For some of the 
studies the focus was not on the differences in affect between OC users and
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non-users (e.g., Sutker, Ubet, Allain, & Randall, 1983). However, in the interests 
of comprehensiveness, all studies involving OC users and non-users filling out 
daily affect rating scales were reviewed if data were published. In the three 
studies where statistical analyses of between-group affect differences were not 
published, the findings discussed below were based on visual inspection of 
published data or graphs (Graham & Sherwin, 1992; 1993; Rouse, 1978; Sutker 
et al., 1983). Studies that did not publish a statistical analysis of the 
differences between the two groups or raw data, were not included (e.g.. 
Gallant, Popiel, Hoffman, Chakraborty, & Hamilton, 1992). The studies by 
Alexander and Sherwin (1993), Forrest (1 979 ), and Tuiten et al. (1995 ) were 
not included in the review as none of these studies included a control group of 
non-OC users and therefore did not allow for affect or mood comparisons 
between users and non-users. (Bancroft and Sartorius [1990] review a number 
of the studies covered in the present review and include an excellent broad 
review of methodological considerations and the effects of OCs on well-being 
and sexuality.)
Examination of the results of 17 studies indicates a great deal of 
inconsistency. Of the 17 studies reviewed, all but 1 study (Marriott & Faragher, 
1986) found group differences in affect between OC users and non-users. 
However, the direction of the differences and the menstrual cycle phases in 
which the differences occur was not consistent across studies. The results of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
10
the Bancroft, Sanders, Warner, and Loudon (1 9 8 7 ) experiment and the Walker 
and Bancroft (1 990 ) study suggest the existence of a pharmacological effect 
of OCs on mood since different types of OCs had different effects. In order to 
clarify the results of the 17 studies, they are summarized below. Since most 
researchers have divided the menstrual cycle into different phases, the four 
most frequently used phases were used for this review and study: all days of 
menstrual flow (menstrual phase), the seven days after menstruation 
(postmenstrual phase), the remaining days leading up to the seven days before 
menstruation (intermenstrual phase), and the seven days before menstruation 
(premenstrual phase). Three types of findings are summarized below: overall 
group effects, differences in variability of affect, and group differences during 
each of the four phases of the menstrual cycle. While most studies examined 
negative affect, a few studies that included positive affect were found.
The majority of the studies found no significant group differences in 
negative affect across the entire menstrual cycle (e.g., Almagor & Ben-Porath,
1991 ; Bancroft & Rennie, 1993; Marriott & Faragher, 1986; Paige, 1971 ; 
Wilcoxon, Schrader, & Sherif, 1976). While two studies did find that OC users 
feel less negative affect across the cycle (Boyle & Grant, 1992; Walker & 
Bancroft, 1990), no studies suggested that OC users were higher than non­
users in negative affect throughout the cycle.
In terms of positive affect, Almagor and Ben-Porath’s (1 9 9 1 ) study
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found group differences. OC users rated themselves higher on positive affect. 
Four other studies, however, did not find group differences in positive affect 
(Boyle and Grant, 1992; Marriott & Faragher, 1986; Moos, 1968; Silbergeld, 
Brast, & Noble, 1971 ). Perhaps the findings of Morris and Udry (1 9 7 2 ) help 
explain this inconsistency for both negative and positive affect. Since one-half 
of the OC users who felt differently, felt “better than usual”, and the other-half 
felt “worse”, it may be that the scores of these two groups cancelled each 
other out to make it look as though there are no differences. Perhaps 
researchers should separate these two groups and look for distinguishing 
characteristics of each group as Bancroft e t al. (1987 ) did when investigating 
premenstrual syndrome (PMS).
The ingestion of the hormones in OCs does seem to provide some sort 
of stabilizing effect of mood. Five studies found that OC users showed less 
variability than non-users in their ratings of affect (Paige, 1971 ; Rouse, 1978; 
Sutker e t al., 1983; Walker & Bancroft, 1990; Warner & Bancroft, 1988). Only 
one study (McFarlane, Martin, & Williams, 1988) did not find any significant 
differences in variability of affect between the two groups. Other studies did 
not examine differences in variability.
The consensus finding during the menstruation phase seems to be that 
OC users experience less negative affect than non-users. Eight studies provide 
findings which support this statement (Boyle & Grant, 1992; Graham &
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Sherwin, 1992, 1993; Moos, 1968a; Paige, 1971; Rouse, 1978; Sutker et al., 
1983; Walker & Bancroft, 1990; Wilcoxon et al., 1972). In contrast, Bancroft 
and Rennie (1993) found that OC users experience a more prolonged pattern 
of negative affect. Three other studies did not find any differences in negative 
affect between the two groups during this phase (Alexander, Sherwin, Bancroft, 
& Davidson, 1990; Almagor & Ben-Porath, 1991; Marriott & Faragher, 1986).
There is no consensus of findings for positive affect during the menstrual 
phase. The authors of two studies reported that OC users experienced less 
positive affect (McFarlane et al., 1988; Warner & Bancroft, 1988), one study 
found that OC users feel more positive affect (Almagor & Ben-Porath, 1991), 
and three studies did not find any differences in positive affect between the two 
groups during menstruation (Boyle & Grant, 1992; Moos, 1968; Rouse,
1978).
For the week after menstruation (postmenstrual phase), the results of 
three studies suggest that OC users experience more negative affect than non­
users (Alexander et al., 1990; Bancroft & Rennie, 1993; Graham & Sherwin,
1992, 1993), findings from one study suggest the opposite (Walker & Bancroft, 
1990), and the results of three other studies found no differences between the 
two groups (Almagor & Ben-Porath, 1991; Marriott & Faragher, 1986; Rouse,
1978). Only two studies have concrete findings regarding differences in positive 
affect for the two groups during the post-menstrual week and they are
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conflicting. Almagor and Ben-Porath (1991 ) found that OC users experience 
more positive affect than non-users during the week following menstruation 
while McFarlane et al. (1 988) found non-users to experience more positive 
affect.
The findings of studies comparing the affect of OC users and non-users 
during the intermenstrual period are inconsistent. Three studies found that OC 
users experience higher negative affect than non-users (Morris & Udry, 1972; 
Paige, 1971 ; Sutker e t al,, 1983). The results of two other studies indicated 
that the OC group experiences less negative affect (Boyle & Grant, 1992; 
Walker & Bancroft, 19 90 ) and four studies found no differences for negative 
affect during the intermenstrual phase (Almagor & Ben-Porath, 1991 ; Marriott 
& Faragher, 1986; Moos, 1968a; Wilcoxon et al., 1976). The findings for 
positive affect were almost as inconsistent. While Almagor and Ben-Porath 
found that OC users experience more positive affect during days 15 to 22, two 
other studies found no differences between OC users and non-users (Boyle & 
Grant, 1992; McFarlane et al., 1988).
Finally, the results of daily rating studies of affect during the 
premenstrual week are just as inconsistent as during the postmenstrual week 
and intermenstrual phase. While the results of four studies found no significant 
differences in negative affect for the two groups during this phase (Alexander 
et al., 1990; Almagor & Ben-Porath, 1991; Graham & Sherwin, 1992; Marriott
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& Faragher, 1986), the findings of four studies suggested that OC users have 
less negative affect (Boyle & Grant, 1992; Moos, 1968a; Paige, 1971; Rouse,
1978). Two other groups of researchers found more negative affect in OC 
users (Sutker et al., 1983; Wilcoxon e t al., 1972), With regard to positive 
affect, the results of four studies suggest no differences between groups for 
the premenstrual week (Boyle & Grant, 1992; McFarlane et al., 1988; Moos,
1968; Rouse, 1978), and two studies suggested that OC users feel more 
positive affect than non-users (Walker & Bancroft, 1990; Warner & Bancroft,
1988). None of the studies suggest that OC users feel less positive affect than 
non-users during the premenstrual week.
Problems with Previous Studies
The above review suggests that there is a great deal of inconsistency in 
the research on differences in affect between OC users and non-users. It is 
unclear whether the inconsistency is due to small sample sizes, the “survivor 
effect" which is discussed below, lack of controls for duration of OC use, the 
lack of consistency among researchers in their choice of affect rating scales, a 
failure of all researchers to independently measure negative and positive affect, 
a failure to separately analyze OC users who experience an increase in negative 
affect and those who experience a decrease in negative affect, or the lack of 
controls for any of the three potentially important psychological or indirect 
pharmacological variables. It is also, of course, possible that there are no real
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differences in affect between the two groups.
One of the main problems with the literature involves the “survivor 
effect” (Kutner & Brown, 1972). The survivor effect refers to the fact that 
women who experience problems while taking OCs stop taking them, which by 
definition leaves a group of women who are not experiencing adverse effects 
(mood or otherwise). Therefore, taking a sample of oral contraceptive users 
and comparing their mood states with never-users involves a huge self-selection 
bias since any women who experience moderate to severe negative mood 
effects would likely have discontinued use of OCs. Roughly 25% of women 
discontinue OC use within one year of use (Trussell & Kost, 1987) and 
depression is in fact one of the most common reasons given for discontinuing 
OC use (Kay, 1984). Therefore, the incidence rates of negative mood change 
associated with being on OCs are likely underestimations in studies using groups 
of women taking OCs for many years.
Three factors can contribute to the survivor effect: (a) the selection 
criteria for the OC user and non-user groups, (b) the length of time which the 
OC users have been taking the OC pill, and (c) the study’s attrition rate. In 
order to minimize survivor effects, researchers should distinguish between 
women in the OC user groups who have been taking the same OC brand since 
the first time they began taking the pill and women who have switched brands. 
The non-user groups should include only women who have never taken OCs and
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not previous users who are no longer taking OCs. The inclusion of “switchers” 
in the user group and of previous users in the non-user group would introduce a 
bias since it may have been negative mood effects which led to switching 
brands or discontinuing use. A study by Deijen, Duyn, Jansen, and Klitsie (1992) 
supports this reasoning. Switchers in this study experienced mood 
improvements on their new brand.
With regards to duration of pill use, it is important to distinguish 
between “early” and “late” use of OCs. While an early use group would still 
contain women who may discontinue OCs in the future due to negative effects, 
a late use OC group would have already lost the women experiencing negative 
mood side effects. Bancroft and Sartorius (1990 ) suggested the use of the 
terms “early use” and “late use” and discussed some of the important 
differences between the early and late use of OCs.
Finally, in prospective studies and controlled experiments comparing OC 
users and non-users, large attrition rates increase the size of the survivor 
effect. It seems logical that a woman just starting on the pill who drops out of 
an experiment would be more likely to do so as a result of negative than 
positive mood side effects. Losing this type of data would make the OC users 
groups appear to be experiencing less negative affect than they actually are.
Thus controlling for the survivor effect involves looking at strict 
definitions of OC users and non-users, duration of use, and attrition rates.
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A second problem with the literature Involves the failure to independently 
measure changes in both positive affect and negative affect. Some studies 
have found that women report mood-enhancing effects when taking oral 
contraceptives (e.g., Almagor & Ben-Porath, 1991 ; Kutner & Brown, 1972; Roy- 
Byme et al., 1984; Worsley, 1980). When positive and negative affect are not 
measured separately, the positive affect changes in some women taking OCs 
and negative affect changes in others may cancel each other out if the overall 
mean score is compared with non-users. Furthermore, these mood 
improvements, combined with the attrition of most women with negative mood 
effects (the survivor effect), leaves a group of women who are taking oral 
contraceptives and potentially experiencing no mood effects, mild to extreme 
positive mood effects, or only mild negative effects on mood. For these 
reasons, a failure to specify the time span of OC use in the sample combined 
with the survivor effect likely underestimates the association between oral 
contraception and negative affect. This reasoning emphasizes the importance 
of independently measuring changes in positive and negative affect and of 
controlling for the survivor effect.
A third problem in the literature is the failure of most researchers to 
control for possible psychological and indirect pharmacological causes of mood 
change due to OC use. The psychological and indirect pharmacological causes 
of mood changes, should they in fact exist, are difficult to determine.
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However, ruling them out would help to determine the direct role of 
pharmacology. Cullberg (1 9 72 ) was one of the first to discuss and control for 
these alternative explanations of differences in negative affect between OC 
users and non-users. Analysis of the literature has revealed at least three 
possible explanations for mood change other than a direct pharmacological 
effect on mood:
1. Expectations of a mood change side effect can lead to mood change 
(or the placebo effect; e.g., Cullberg, Gelli, & Jonsson, 1969). Women who are 
aware of the possibility of mood changes with oral contraceptive use may be 
more likely to experience them. A “scapegoat effect” may result from this 
where unhappiness due to life circumstances or relationships is attributed to 
“the pill”. Women may have expectations of negative or positive mood change.
2. The symbolic effect of the ‘anti-baby pill’ (Cullberg, 1972) may also 
lead to changes in mood. Some women may become depressed due to feelings 
of guilt over preventing the conception of a child. On the other hand, other 
women may experience mood improvements due to the increased reassurance 
they feel about not getting pregnant. This may also lead to increased sexual 
satisfaction.
3. Mood changes may also occur secondary to somatic side effects (an 
indirect pharmacological effect). Women experiencing weight gain, decreased 
libido, or nausea may become depressed or irritable as a result of this. Others
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who experience a regulation of their menstrual cycle, a desired breast size 
increase or decrease, or a clear-up of acne may experience an improvement in 
mood.
Since two psychological factors and the indirect pharmacological factor 
could hypothetically lead to an improvement or deterioration in mood, pre-test 
measures of each should be included when attempting to determine the cause 
of a mood change associated with oral contraceptive use. Pre-test measures 
of expectations, symbolic effect attitudes, and the desirability of somatic 
changes should be predictive of the direction of mood change if these 
psychological or indirect pharmacological factors play a role in causation. 
However, it is important to realize that the correlation of any of the three 
factors with the predicted mood change does not rule out the possibility of a 
pharmacological effect. More than one factor could be responsible for the 
mood change. None of the studies reviewed above controlled for all three of 
these variables.
In order to control for the three non-pharmacological causes of mood 
change noted above, some controls can be used. The first two factors, 
expectations and the symbolic “anti-baby” factor, can be ruled out as entirely 
responsible for mood change if different hormone dosages are compared and 
found to result in different degrees of mood change. However, differential 
mood change based on hormone content would not rule out the possibility of
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the mood changes occurring secondary to somatic side effects. Therefore 
other controls are needed. The best way to see how the psychological and 
indirect pharmacological factors affect mood would be to give three pre-test 
questionnaires to the subjects before their mood had been measured or 
assessed. The first questionnaire could assess women's schemas and 
expectations regarding OCs and side effects, including mood change. If high 
correlations exist between negative mood and expectations or awareness of 
this type of mood change, then expectations cannot be ruled out. The same 
reasoning applies to positive affect. The second questionnaire should ask 
about their feelings regarding the prevention of the possible conception of a 
child. It should assess guilt and/or reassurance and then see if the responses 
can predict negative or positive moods. A third questionnaire could assess the 
somatic side effects that a women may experience due to OC use and the 
desirability of these side effects. If negative mood is associated with 
undesirable somatic side effects and positive mood with desirable somatic side 
effects then this indirect pharmacological factor cannot be ruled out. Somatic 
side effects should then be monitored throughout a prospective study. The 
ability of these three pre-test questionnaires to predict negative or positive 
mood in OC users could give an indication of the effect of the two psychological 
and one indirect pharmacological factors on mood.
In summary, the early research on the relationship between OC use and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
21
mood change suggests three guidelines for future research examining 
differences in mood between OC users and non-users. First, subjects taking 
OCs should be defined as long-time users or first-time users when investigating 
the effects of OCs on mood. Any long-time user studies may include an 
underestimation of negative mood side effects due to the survivor effect. 
Second, independent measures of positive and negative affect should be 
included as both types of mood change have been reported. Finally, 
psychological and indirect pharmacological factors that could affect mood 
should be assessed to determine the role which they may play.
The Present Studv
The present study attempted to examine the relationship between OC 
use and affect and to determine whether controlling for the above confounds 
could account for the conflicting findings of previous researchers. Ninety-six 
undergraduates (17 first-time OC users, 34 long-time users, and 45 never- 
users) filled out the Positive and Negative Affect Schedule (PANAS; Watson, 
Clark, & Tellegen, 1988) and the Menstrual Distress Questionnaire Form T  
(MDCi Moos, 1968, 1989) daily for 35 days. The present study is the first to 
examine positive affect variability and to investigate the survivor effect by 
directly comparing early, late, and never users of OCs. This study also assesses 
the indirect pharmacological and psychological variables which could be 
affecting mood or affect.
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A number of additional possible moderating variables were also included 
on an exploratory basis. These were presence/absence of: self-diagnosed 
premenstrual syndrome history (PMS), family history of mental illness, and 
personal history of mental illness. PMS was included due to the putative 
relationship between hormones and mood while family and personal psychiatric 
history were included as they could reflect possible vulnerability factors to 
mood change.
While the present study was mainly exploratory, the literature suggested 
two main hypotheses. Hvoothesis 1 : First-time OC users experience higher 
negative affect and lower positive affect than long-time users and never-users. 
This logically deduced prediction arises from three lines of reasoning. First, 
plausible pharmacological mechanisms have been hypothesized through which 
OCs could affect mood. Second, the lack of consistency between studies 
regarding subject’s duration of OC use may account for inconsistent findings 
regarding mood differences between users and non-users. Third, using a first­
time user group eliminates the survivor effect and means that women who may 
eventually stop using OCs due to negative changes in mood are included in the 
sample. The use of a never-user as opposed to a non-user group also 
eliminates those women who had negative mood experiences when taking OCs. 
Hvoothesis 2: Long-time OC users experience more stabilitv of negative affect 
and positive affect than never-users and first-time users. This hypothesis was
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based on a review of previous studies which indicated that OC users 
experienced less variability in their ratings of affect than non-users. Finally, if 
either of the two hypotheses listed above were supported, a number of 
statistical tests would be conducted to rule out competing explanations for the 
differences (e.g., expectations of mood change, the symbolic effect of the pill, 
or mood change secondary to somatic side effects).
Method
Subiects
One-hundred and twenty-nine women (20 first-time OC users, 52 long­
time users, and 57 never-users) were recruited to participate in this study. 
Recruitment was targeted at introductory psychology classes, upper-year 
psychology classes, any-year volunteers from other disciplines, clients seen at 
the university health clinic, clients seen at the Thunder Bay District Health Unit, 
clients seen at the Port Arthur Clinic, clients seen by area physicians, and 
women who responded to a radio interview or notices posted on bulletin 
boards around campus or in the city newspapers. However, 128 (99 .22% ) of 
the volunteers were university students. All women were 18 years or older. 
Introductory psychology student volunteers received three points towards their 
final course grade if they completed the entire study and one point if they only 
completed the initial questionnaire. All other participants received ten dollars at
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the completion of all three stages of the study.
Six women ( 1 first-time user, 3 long-time users, and 2 never-users) did 
not complete the study (4 .65 %), a very low attrition rate. Reasons for the 
loss of subjects included: (a) moving out of town during the course of the 
study (1 first-time user), (b) failure to complete the 35 daily rating 
questionnaires (3 long-time users), (c) illness following surgery (1 never-user), 
and (d) failure to complete stage 3 due to a busy schedule (1 never-user).
Subject data were excluded from analysis if the subject: (a) was a long­
time user who had taken more than one brand of OC pill (i.e., “switchers” ; n =  
15), (b) was a first-time user who had previously taken OCs and was starting 
again (n = 2), (c) had previously delivered a child (n = 4), (d) had a current 
and/or chronic medical disorder that could affect emotional states (e.g., 
hypothyroidism; n =  2) (e) was pregnant (n = 1 ), (f) was presently taking a 
medication that could effect emotional states (e.g., Anaprox or lithium 
carbonate; rv= 6), (g ) did not menstruate during the 35 days of the study (n =
1 ) (h) was lactating (n = 0), or (i) was hysterectomized (n = 0). Four women 
were excluded based on two or more of the above criteria.
In total, 96 women (17  first-time OC users, 34 long-time users, and 45  
never-users) completed the study and had usable data based on the exclusion 
criteria. The women ranged in age from 18 to 27  (M = 19.84) and their years 
of education ranged from 13 to 19 (M = 14.41 ). The majority of the women
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were single as only 7.29% were married or cohabitating. Of the OC users, 
54.90%  were taking monophasic preparation OCs in which the dosage of 
estrogen and progestin remains constant for the entire 21 days, and 45.10%  
were taking triphasic preparation OCs in which the dosages of estrogen and/or 
progestin change three times over the 21 days (see Appendix A). The first­
time user group consisted of women who had begun taking OCs for the first 
time within the previous 60 days. These women had been taking OCs for a 
mean of 1.00 months (SO = 0 .79 ). The long-time user group included women 
who had taken one brand of OCs for more than two years. Their mean months 
of OC use was 36.71 ( ^  = 16 .76). The never-user group consisted of women 
who had never taken OCs.
Measures
Three self-report instruments were used: an Initial General Information 
Questionnaire (IGIQ), the Daily Rating Questionnaire (DRCJ), and a Final General 
Information Questionnaire (FGIQ).
Initial General Information Ouestionnaire. The IGIQ (Appendix B) consisted 
of seven sections: demographic information, medications and medical 
conditions, relationship information, personal and family psychiatric history, 
reproductive history, contraceptive information (including attitudes), and 
substance use. This questionnaire was developed by the author specifically for 
this study. The anxiety and depression subscales from the Symptom-Checklist-
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90-Revised (Derogatis, 1994) were also included.
Dailv Rating Ouestionnaire. The DRQ (see Appendix C) contained the 
Positive and Negative Affect Schedule (Watson, Clark, & Tellegen, 1988), the 
Menstrual Distress Questionnaire Form T (Moos, 1968, 1989), and four 
additional physical symptom items which were added by the author (i.e., weight 
loss, breast size increase, breast size decrease, and clearer complexion).
These symptom items were added to both reflect somatic symptoms which 
could possibly lead to changes in positive affect and to counterbalance the 
many unpleasant somatic items.
The 20-item PANAS is designed to independently measure both positive 
affect (PA) and negative affect (NA). Subjects were instructed to rate each 
adjective on a five-point scale reflecting the extent to which they have 
experienced the emotion during the past 24 hours. The scale ranges from 1 
(very slightly or not at all) to 5 (extremely). The two scales of the PANAS 
have been shown to have sound psychometric properties (Watson, Clark, 
Tellegen, 1988). Internal consistencies for the PA and NA scales respectively 
are .90 and .87. The PA-NA correlation is -.12, which means the two scales are 
reasonably uncorrelated. Test-retest reliability of daily ratings for PA and NA 
are .47 and .39. Finally, the correlations between PA and NA and the Hopkins 
Symptom Checklist overall score (-.29, .65) and the Beck Depression Inventory 
(-.35, .56) suggested adequate validity.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
27
The MDQ includes 47 items which assess affective, somatic, and 
behavioural symptoms that might occur during the menstrual cycle. Eight 
scales are included: pain, water retention, autonomic reactions, concentration, 
behaviour change, negative affect, arousal, and control. Each symptom within 
each of these scales is rated on a five-point scale ranging from 0 (none) to 4 
(severe). The subject is required to choose the category which best describes 
their experience for that day. A 48th item is also included to determine if the 
menstrual flow is occurring. The primary purpose of the MDQ in this study was 
to monitor somatic symptoms. Markum (1 9 7 6 ) found the MDQ Form T to 
have high test-retest reliability for the overall score (from .80 to .88) when a 6- 
point rating scale was used. She also found that split-half reliabilities ranged 
from .82 during the menstrual phase to .98 during the premenstrual phase. 
Research by Busch, Costa, Whitehead, and Heller (1 988 ) found that severity of 
MDQ perimenstrual symptoms was related to frequency of health care seeking 
and work absenteeism due to gynecological disorders. This study, as well as 
studies using the MDQ to measure premenstrual symptom reduction following 
placebo-controlled treatment (e.g., Dennerstein e t al., 1985; Facchinetti et al.,
1989), attest to the validity of this questionnaire.
Final General Information Questionnaire. The FGIQ (Appendix D) included 
the same seven sections as the IGIQ, with two additional parts. OC users were 
asked about the regularity and time of day of taking their pills, the number of
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pills which they missed or took late, and about their reasons for taking OCs. All 
OC users were first asked whether they believed OCs affect mood in general 
and secondly, if they believed their mood had been negatively or positively 
affected.
Procedure
The study consisted of three stages. During Stage 1, the women met in 
mixed groups with the experimenter. They were told that the study was an 
examination of the psychological and emotional effects of contraception. It 
was emphasized that participation was voluntary, that subjects could 
withdraw at any time without penalty, and that all data were anonymous and 
confidential. All subjects read and signed the consent form (see Appendix E) 
and then completed the IGIQ. This took approximately 20 minutes. Each 
subject was then given a package containing instructions and 35 of the Daily 
Rating Questionnaires. The women were told that they would be required to fill 
out a questionnaire daily for 35 days (Stage 2) and then return to complete a 
final questionnaire (Stage 3). A date, time, and place was given for Stage 3 of 
the study. Each women was then given the opportunity to ask questions. At 
this point the volunteers from the first year psychology classes were given one 
point towards their final course mark for participating.
Stage 2 involved having the women fill out a DRQ each evening for 35 
days beginning the same day that they completed the initial questionnaire.
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Women in the first-time user group who had not yet started taking OCs filled 
out the DRQ on the first day of OC use. Each woman also received one phone 
call from the experimenter near the end of Stage 2 to confirm the final 
appointment time and to address any questions or concerns which the woman 
may have had.
Once a woman had completed all 35 DRQs she returned to the university 
at the meeting time given during Stage 1 in order to complete Stage 3. The 
women filled out the FGIQ and then received a Debriefing Form (Appendix F). At 
this time the women received either their $1 0  or their final 2 points towards 
their mark (first year psychology students) for participating. Those women 
who did not show up for their appointment were rescheduled until they 
completed the FGIQ or until they withdrew from the study.
Data Reduction and Analvses
The 35 DRQs were numbered based on each woman’s menstrual cycle. 
For each woman, day 1 was the first day of menstruation and the last day 
used in the analysis was the last day before menstruation (e.g., most often 
between days 28 and 35 ). The number of data days used for each woman 
was dependent on either the length of the woman’s cycle or where her 
menstrual period fell during the 35 days of the study.
For each subject, the menstrual cycle was partitioned into four 
menstrual cycle phases (MCPs): menstrual phase (all days of menstrual flow).
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postmenstrual phase (the seven days after menstruation), intermenstrual 
phase (the remaining days leading up to the seven days before menstruation), 
and premenstrual phase (the seven days before menstruation). Two phases 
were of a fixed length and two phases of variable length. The exception was 
one subject in the first-time user group who had a menstrual cycle length of 
only 18 days. Her postmenstrual and premenstrual phases consisted of only 
five and four days respectively.
Daily positive affect, negative affect and four of the MDQ scale scores 
(pain, water retention, autonomic reactions, and control) were then calculated 
for each subject. In the rare instances where items were missed, the item’s 
score was estimated by taking the item’s scores from the preceding and 
following days and calculating the mean. In total approximately 225 of the 
115,200 items (0 .20% ) were missed. From the daily scores, a mean and 
variability score for the six scales was calculated for each phase for each 
woman. The variability scores measured the variance of the daily scores within 
each phase. The above calculations resulted in four mean scores and four 
variability scores for each woman for positive affect, negative affect, pain, 
water retention, autonomic reactions, and control (48  scores in total).
The same basic design was used for the main and supplementary 
analyses: a 3 between (never-users, first-time users, long-time users) X 4 
within (menstrual phase, postmenstrual phase, intermenstrual phase.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
31
premenstrual phase) mixed MANOVA . The dependent variables used in the 
main analyses were mean positive and negative affect scores, or variability in 
positive and negative affect scores.
Results 
Prelimlnarv Analvses 
Internal Consistencv and Reliabilitv of Measures
Cronbach’s alpha coefficients were calculated for the two PANAS 
subscales and the four MDQ scales. Two days (days 10 and 15) were used in 
the calculations. The internal consistency of the positive affect, negative affect 
and total somatic symptom scales were quite good. For positive affect the 
alphas for days 10 and 15 were .93 and .94 with a mean of .93. The two daily 
and one mean alphas for the other scales were: negative affect (.82, .83, .83), 
pain, (.67, .69, .68), water retention (.35, .25, .30), autonomic reactions (.70, 
.35, .53), control (.79 , .65, .72), and total somatic symptom (.86, .80, .83).
The reliability of three additional independent variables were calculated using 
Pearson product-moment correlation coefficients. Correlations between IGIQ 
and FGIQ responses to questions assessing the presence of a diagnosed or 
suspected family history of mental illness, r = .81, g  < .001; a diagnosed or 
suspected personal history of mental illness, r = .80, g  < .001 ; and a diagnosed 
or suspected premenstrual syndrome history, r = .70, g < .001, suggest that 
test-retest reliability was adequate.




Prior to any analysis, the distributions of mean and variability scores for 
positive affect, negative affect, pain, water retention, autonomic reactions, and 
control for each group/phase combination were examined for the presence of 
univariate outliers. Any values which exceeded three standard deviations above 
or below the mean were replaced with this (M ± 3SD) value. In total, twenty- 
six outliers were removed from the 48  affect cells while 63 outliers were 
removed from the 96  somatic cells. These outliers represented 1.7% and 2.1%  
of the data points. Appendices G and H list the cells which contained outliers 
for the affective and somatic MANOVAs respectively.
Assessing Multivariate Assumptions
Before undertaking analyses to test the main hypotheses, the data were 
examined to ensure that the assumptions of MANOVA were met. Graphical 
checks of linearity indicated that it was adequate for all dependent variables. 
Multivariate normality of the distributions was assessed using both statistical 
and graphical methods. Criteria for normality included passing a visual check of 
the distribution of scores as well as using the formula (skewness 4 - standard 
error of skewness) < 3 (Tabachnick & Fidell, 1996). The assumption of 
normality was judged satisfactory for the positive affect mean and variability 
score distributions while the ten other distributions were positively skewed.
Box’s M multivariate test for homogeneity of dispersion matrices found
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
33
adequate homogeneity of variance-covariance matrices for negative and 
positive affect mean scores F(72, 8203 ) = 1.20, g > .05, Univariate Box’s M 
tests on negative and positive affect variability ranged from F(2, 13117) =
12.75, g <  .001 to F(2,l 3117) = 0.29, g >  .05 with a mean F value of 3.39. 
Univariate Box’s M tests on the four somatic mean scores ranged from F(2, 
13117) = 21.91, g < .001  to £ (2 ,13117) = 1.13, g > .05 with a mean F of 
7.95, g < .05. The Box’s M tests on the variability scores ranged from F(2, 
13117) = 18.97, g < .001 to £ (2 ,13117) = 0.43, g >  .05 with a mean £ of 7.35, 
g < .05. Groups with smaller sample sizes also produced larger variance scores 
than the larger groups.
Multicollinearity was not a problem for the positive and negative affect 
mean scores since correlations within groups ranged from r = .14 , 
g > .05 to r = -.51, g < .05 with a mean within-group correlation of .02, 
g > .05 and an overall (collapsed across groups) correlation of r = -.07, g > 
.05. Within-group correlations for positive and negative affect variability scores 
ranged from r = .29, g > .05 to r = .16, g > .05 with mean of r = .26, g > .05, 
and an overall (collapsed across groups) correlation of r = .26, g < .05. As 
reported in Appendix I, all but one of the four somatic scales mean and 
variability scores were significantly correlated with each other. The correlations 
between mean somatic symptom scale scores ranged from r = .56, g < .001 
to r = .82, g  < .001 with a mean of r = .64, g  < .001. The correlations between
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mean somatic symptom variability scale scores ranged from r = .19, g > .05 to 
r = .57, g < .001 with a mean of r = 0 .44 , g  < .001.
As a result of the above tests of multivariate assumptions the following 
decisions regarding data analysis were made. First, a MANOVA was 
performed on both mean and variability affect scores using an alpha level of 
.05. Significant MANOVAs were followed up with univariate ANOVAs. A 
Bonferroni correction (.025) was used on the alpha levels within each ANOVA. 
Newman-Keuls post-hoc comparisons were done on significant effects and 
interactions with an alpha level of .025. Second, the unweighted-means 
approach was used in all MANOVAs and ANOVAs to control for increases in 
Type I  error due to unequal sample sizes between groups (Tabachnick &
Fidell, 1996, p. 48 ). Third, the conservative Pillai’s criterion for evaluating 
multivariate significance was used in all analyses to compensate for 
heterogeneity of variance as suggested by Tabachnick and Fidell (1996 , p.
382). Finally, the four somatic scales were combined into one to solve the 
multicollinearity problem. The four scale scores were summed and divided by 
the number of items to obtain a total somatic symptoms score. Mean and 
variability somatic scores were calculated for each woman for each phase of 
the cycle.
Assessing Group Eauivalencv
As shown in Table 1, the three groups of women were not significantly




Means and Standard Deviations or Raw Frequency and Percentages for the  Nine Variables Used 
to  Assess Group Eauivalencv Across the Three Groups
Variable Never Users First Time Users LongTime Users
N = 45 N = 17 N = 34
Means (Standard Deviations)
Age (years) 19.62 (1 .4 2 ) 19.76  (1 .1 5 ) 2 0 .1 8  (1 .9 5 )
Education (years) 14.22 (0 .7 9 ) 14 .47  (0 .8 0 ) 1 4 .6 2  (1 .3 0 )
Height (cm) 166 .90  (5 .7 4 ) 167 .79  (8 .1 0 ) 1 6 5 .9 9  (6 .3 0 )
Weight (kg) 6 4 .77  (1 2 .8 0 ) 6 3 .63  (1 0 .5 7 ) 6 3 .4 8  (9 .7 0 )
Alcohol Frequ. Score 1.29 (0 .7 3 ) 1 .24 (0 .7 5 ) 1 .55 (0 .6 7 )
Alcohol Concump. Score 1.56 (0 .8 7 ) 1.29 (0 .7 7 ) 1 .58  (0 .7 1 )
Illegal Drug Use Score 0 .16  (0 .4 2 ) 0 .1 2 (0 .3 3 ) 0 .1 8  (0 .4 6 )
Raw Frequency (Percentage)
Relationship Status
partner 18 (4 0 .0 0 ) 13 (7 6 .5 0 ) 28  (8 2 .4 0 )
no partner 27 (6 0 .0 0 ) 4  (2 3 .5 0 ) 6 (1 7 .6 0 )
Sexual Status
never had sex 27 (6 0 .0 0 ) 2 (11 .80 ) 1 (3 .0 0 )
no sex in 35 days 7 (1 5 .6 0 ) 7 (41 .20 ) 3 (9 .1 0 )
sex during study 11 (2 4 .4 0 ) 8 (47 .10 ) 2 9  (8 7 .9 0 )
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different in terms of age, F(2, 9 5 ) = 1.20, g > .05; years of education, F(2, 95) 
= 1.54, g > .05; height, F(2, 95 ) = 0.47, g > .05; weight, F(2, 95) = 0.14, g > 
.05; frequency of alcohol consumption, F(2, 94 ) = 1.60, g > .05; amount of 
alcohol consumption, F(2, 94) = 0 .80, g > .05; or frequency of illegal drug use, 
F(2, 94) = 0.13, g >  .05. There were, however, significant relationships between 
group membership and whether or not one had a romantic partner,
(2, N = 96) = 16.63, g < .01, and one’s level of sexual activity during the 
study, (4, N = 95) = 44 .07 , g  < .01. Since women who take oral 
contraceptives usually do so because they are in a relationship and sexually 
active, these group differences likely reflect true population differences. 
Fortunately sexual status does not affect positive or negative affect scores,
Fs (2 , 118) = 2.18 and 2.12, g  > .05. However, while relationship status does 
not affect positive affect scores, t  (8 0 .48 ) = 0 .72, g > .05, relationship status 
does seem related to negative affect scores, t  (1 1 8 .9 6 ) = 2.74, g < .05. The 
women in romantic relationships experienced more negative affect than women 
not in such relationships. There was no relationship between relationship status 
and positive or negative affect variability scores, ts (94 ) = 0.79 and 1.40, gs > 
.05.
Simple Descriptive Data
Tables 2 and 3 list the overall mean scores and mean variability scores 
for positive and negative affect for the three groups of women across the four




Mean Negative and Positive Affect Scores for the Three Groups Across the Four 
Phases of the Menstrual Cvcle
Positive A ffect Negative A ffect




1 2 3 4 (group
mean)
Never 13.56 1 3 .54 1 3 .9 5 14 .26 13.83 5 .0 8 5 .14 5.05 5 .15 5 .10
Users (7 .7 2 ) (7 .1 5 ) (6 .9 3 ) (7 .3 1 ) (6 .7 7 ) (5 .0 3 ) (5 .3 2 ) (5 .0 9 ) (4 .6 7 ) (4 .5 1 )
First Time 14.23 14.91 14.31 13.62 14.27 7 .0 0 7 .09 7 .30 6 .76 7 .0 4
Users (7 .1 0 ) (7 .4 0 ) (8 .7 7 ) (7 .3 7 ) (6 .8 9 ) (6 .6 4 ) (6 .5 6 ) (6 .3 6 ) (5 .6 9 ) (5 .9 1 )
Long Time 12.42 12 .38 1 2 .8 0 13.06 12.66 5 .5 9 5 .4 0 5 .73 5 .05 5 .44




(7 .5 2 )
1 3 .3 7
(6 .8 3 )
13.61
(6 .9 3 )
13.72
(6 .7 4 )
5 .6 0
(5 .6 7 )
5 .5 7
(5 .5 7 )
5 .69
(5 .1 3 )
5 .40
(5 .4 0 )
N ote. Phase 1 =  menstrual; Phase 2  = postmenstrual; Phase 3 =  intermenstrual; Phase 4  = 
prem enstrual.




Mean Negative and Positive Affect Variability Scores for the Three Groups Across the 
Four Phases of the Menstrual Cvcle







Never 17.48  2 2 .7 8  2 8 .0 3  2 7 .0 9  2 3 .8 4
Users (2 0 .1 5 ) (1 6 .7 2 ) (6 .9 3 )  (2 2 .5 4 )  (1 5 .5 9 )
First Tim e 2 2 .69  2 4 .2 6  2 2 .5 3  2 7 .5 5  2 4 .2 6
Users (2 5 .0 2 ) (2 0 .4 6 )  (2 5 .3 8 )  (2 2 .4 8 )  (1 7 .6 0 )
Long Time 11.71 2 1 .6 6  2 6 .5 7  2 4 .3 6  2 1 .0 8
Users (9 .1 2 ) (2 0 .7 6 ) (2 3 .3 8 )  (16 .61  ) (1 2 .0 4 )
10.86 11.35  1 3 .6 0  18 .14  13.49
(1 7 .9 4 ) ( 1 2 .7 4 ) 0 8 .1 2 ) (2 9 .6 1 )  (1 5 .6 6 )
13.58 12 .54  1 6 .6 8  17 .57  15.09
(1 7 .9 8 ) ( 1 6 .0 5 ) 0 5 .2 7 )  (1 8 .5 0 ) (1 0 .3 4 )
9 .00  13 .47  1 7 .7 4  14.44  13 .66
(1 5 .7 4 ) ( 1 9 .3 5 ) 0 9 .1 5 ) 0 6 .1 5 )  (1 3 .9 5 )
Phase 16 .36  2 2 .6 4  2 6 .5 4  2 6 .2 0
Means (1 8 .3 8 ) (1 8 .7 2 ) (2 2 .6 0 )  (2 0 .4 5 )
10.68 12.31 15.61 16.73
(1 7 .1 6 ) (1 5 .8 0 ) (1 7 .9 6 ) (2 3 .6 0 )
Note. Phase 1 = menstrual; Phase 2 = postmenstruai; Phase 3 = intermenstrual; Phase 4 = 
premenstrual.
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phases of the cycle.
Main Analyses
Relationship Between OC Use and Positive and Negative Affect Means
A 3 (group) X 4  (menstrual cycle phase) mixed MANOVA was performed 
on mean daily positive affect scores and mean daily negative affect scores. 
There was no group effect for positive or negative affect, F(4, 186) = 0 .77, e  > 
.05. Similarly, there was no main effect for menstrual cycle phase, F(6, 558) = 
0.22, B > .05, or the group X menstrual cycle phase interaction, F(12, 558) = 
0.34, B > .05. The absence of a group effect did not support hypothesis 1: 
First-time OC users experience higher negative affect and lower positive affect 
than long-time users and never users.
Relationship Between OC Use and Positive and Negative Affect Variability
A 3 (group) X 4  (menstrual cycle phase) mixed MANOVA was performed 
to test hypothesis 2: Long-time OC users experience more stability o f negative 
affect and positive affect than never-users and first-time users. While there 
was no significant group effect for positive or negative affect variability scores, 
F(4, 186) = 0.25, B > .05, there was a significant phase effect, F(6, 558) =
3.55, B < .01, but no group X phase interaction, £ (12 , 558) = 0.75, b  > .05. 
Hypothesis 2 was not supported since no differences in affect variability scores 
were found between the never-user, first-time user, or long-time user groups.
A follow-up 3 (group) X 4  (menstrual cycle phase) mixed ANOVA performed on
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negative affect variability scores did not reveal an effect for group, F(2, 93) = 
0.08, B > .025; phase, F(3, 279) = 2.84, b  > .025; or for their interaction, F(6, 
279) = 0.66, B > .025. The identical ANOVA performed on positive affect 
variability scores revealed a significant main effect for phase of the menstrual 
cycle, F(3, 279) = 5.54, B < 01. The main effects for group and the group X 
phase interaction were not significant, F(2, 93 ) = 0.42, b > 025; F(6 , 279) = 
0.91, B> .025.
As illustrated in Figure 1, Newman-Keuls Post Hoc tests revealed that the 
women experienced significantly less variability in positive affect during the 
menstrual phase than during the postmenstruai phase, g (279 ) = 6.28, b  < .01 ; 
the intermenstrual phase, g (2 7 9 ) = 10.18, g < 01; and the premenstrual 
phase, g (279 ) = 9 .84, g < -01. In other words, the womens day-to-day 
positive affect variability scores were more stable during menstruation than 
during any other phase of their cycle.
SuDDlementarv Analyses
Exploration of Pill Tvoe
The following analyses were undertaken in order to explore whether a 
failure to distinguish between OC type (monophasic versus triphasic) in the main 
analyses could be obfuscating any main effects. Four separate 2 (first-time 
users, long-time users) X 2 (monophasic users, triphasic users) X 4  (menstrual 
cycle phases) mixed ANOVAs were done on mean positive affect, mean





2 6  -
2 4  -
22  -
2 0 -
menstrual postmenstruai intermenstrual premenstrual
Menstrual Cycle Phase
Figure 1. Mean positive affect variability scores for all women across the four 
menstrual cycle phases. The menstrual and intermenstrual phases differ 
significantly on positive affect variability. Vertical lines depict standard errors 
of the mean.
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negative affect, mean positive affect variability, and mean negative affect 
variability. For positive affect variability, both the OC type X phase interaction 
and the pill user group X OC type X menstrual cycle phase interactions were 
significant, Fs (3, 141) = 4.55 and 3.56, p < .01 and .025, respectively (see 
Table 4  for the mean scores).
Separate ANOVAs for the two OC types found a phase effect for the 
triphasic OC users, F (3, 63) = 4 .86 , p < .01, and a pill-user group X menstrual 
cycle phase interaction for the monophasic OC users, F (3, 78 ) = 5.09, p < .01. 
Post hoc analysis of these findings revealed that the triphasic OC users 
experienced more positive affect variability during the intermenstrual phase 
than the menstrual phase, g (7 8 ) = 16.19, p < .025, while no phase effect was 
found for the monophasic users, F (3 , 78) = 2.37, p > .05, (see Figure 2). 
Separate examination of the first-time and long-time users revealed a phase 
effect for the long-time users, F (3, 96 ) = 5.31, p < .01, and an OC type X 
menstrual cycle phase interaction for the first-time users, F (3, 45 ) = 6.48, 
p < .01. The long-time user phase effect is similar to that depicted in Figure 1.
Examination of the menstrual phase found that: (a) first-time users had 
higher positive affect variability than the long-time users, F (1, 50) = 8.42, p  < 
.01 ; (b) monophasic OC users had significantly higher positive affect variability 
than the triphasic users, F (1, 50) = 7.18, p  < .025; and (c) there was a pill- 
user group X OC type interaction, F (1, 50) = 6.15, p < .025 (see Figure 3).




Mean Positive A ffect Variability Scores as a Function of OC-Tvpe Group. Pill-Use Group, and 
Phase of the Menstrual Cvcle
Group 1
Phase
2 3 4 (group
mean)
First-Tim e Users
monophasic 36 .4 4 2 8 .0 5 11.51 39.81 28.95
(N =7) (3 1 .1 4 ) (2 5 .3 6 ) (8 .5 6 ) (2 3 .1 3 ) (2 2 .0 4 )
triphasic 13.06 21.61 30.25 1 8 .9 6 20 .97
(N = 10) (1 4 .7 0 ) (1 7 .2 1 ) (3 0 .5 8 ) (1 8 .5 2 ) (2 0 .2 5 )
Long-Time Users
monophasic 12.06 2 2 .2 2 26.38 2 5 .6 9 21 .59
(N = 34) (9 .4 7 ) (2 0 .6 5 ) (2 7 .3 5 ) (1 4 .6 7 ) (1 8 .0 4 )
triphasic 11.15 2 0 .7 6 26 .87 2 2 .2 2 20 .25
(N = 21 ) (8 .8 9 ) (2 1 .7 7 ) (1 6 .0 1 ) (1 9 .8 1 ) (1 6 .6 2 )
Phase 15.37 2 2 .5 3 25.22 2 5 .4 2
Means (1 6 .8 1 ) (2 0 .4 9 ) (23 .88 ) (1 8 .6 1 )
Note. Phase 1 = menstrual; Phase 2 = postmenstruai; Phase 3 = intermenstrual; Phase 4  = 
prem enstrual.














menstrual postmenstruai intermenstrual premenstrual
-0--------  triphasic users
♦ ■ monophasic users
Menstrual Cycle Phase
Figure 2. Mean positive affect variability scores across the menstrual cycle as 
a function of OC type. While the menstrual and intermenstrual phases differ 
significantly for the tripasic users, there are no significant between-phase 
differences for the monophasic users.











First Time Users Long Time Users
monophasic users 
triphasic users
m -U se  G raap
Figure 3. Mean positive affect variability scores during the menstrual phase as 
a function of pill-use group and the OC type. The first-time monophasic users 
had significantly higher positive affect variability than the other three groups.
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First- time OC users taking monophasic preparations experienced significantly 
more positive affect variability during the menstrual phase than long-time 
monophasic users, g  (50) = 24.38, e  < .01, first-time triphasic users, g (5 0 ) = 
23.38, B < .01, and long-time triphasic users, g (50) = 25.29, g <  .01. 
Exploration of Potentiallv Important Individual Difference Variables 
As presented above, the main analyses did not find any group 
differences in positive or negative affect mean or variability scores. Data had 
been collected for three potentially important individual difference variables 
namely premenstrual syndrome history, family mental illness history, and 
personal mental illness history. Therefore, three MANOVAs were undertaken to 
explore whether the three OC user groups differed in positive or negative affect 
mean scores or variability scores when the groups were further divided based 
on these variables.
Premenstrual Svndrome. Self-diagnosis of premenstrual syndrome (PMS) 
(yes, no, or unsure) was the first variable explored in two 2 (never-user, long­
time user) X 3 (no PMS, PMS, unsure of PMS) X 4  (menstrual cycle phase) mixed 
MANOVAs. The first-time user group was excluded since only one woman fell 
into the PMS cell. The mean scores for the 48 cells of the MANOVA on mean 
affect scores are listed in Appendix J. The results of the MANOVA on mean 
scores did not find any significant main effects or interactions (see Appendix 
K). However, analysis of the mean variability scores (see Table 5) found a




Mean Positive and Negative A ffect Variability Scores as a Function of Pill-Use Group. PMS Group, and 
Phase o f the Menstrual Cvcle
Positive A ffect Negative A ffect
Phase
Group 1 2 3 4 (group
mean)
1 2 3 4 (group
mean)
Never Users
no pms 17.71 17.92 24.81 2 5 .8 4 2 1 .5 7 11 .59 9 .9 2  12.44 19.93 1 3 .4 7
(N =18) (2 2 .4 5 ) (1 1 .4 2 ) (1 9 .6 6 ) (1 6 .6 1 ) (1 3 .2 3 ) (1 7 .0 9 ) (1 1 .0 0 ) (1 9 .9 1 )  (3 5 .5 9 ) (1 7 .2 5 )
pms 1 8 .6 0 25.07 3 0 .52 3 1 .4 5 26.41 1 4 .1 4 1 0 .44  14 .80 2 1 .5 9 1 5 .2 4
(N =16) (1 8 .0 0 ) (1 7 .3 2 ) (1 7 .5 6 ) (3 0 .4 2 ) (1 7 .2 6 ) (2 3 .4 5 ) ( 1 1 .9 4 ) (1 3 .9 7 ) (3 1 .3 1 ) (1 7 .3 2 )
unsure 16 .69 27 .54 2 8 .3 6 2 4 .5 6 2 4 .2 9 3 .43 1 5 .22  13.59 10 .84 1 0 .7 7
(N =10) (2 0 .1 6 ) (2 3 .1 9 ) (3 0 .0 6 ) (1 7 .9 4 ) (1 8 .3 6 ) (3 .9 4 ) (1 7 .4 5 ) (2 2 .9 3 )  (1 2 .2 3 ) (1 1 .1 0 )
Long-Time Users
no pms 13.61 28.25 2 0 .3 4 30.01 2 3 .0 5 3.11 1 9 .92  15.13 2 7 .2 4 1 6 .35
(N=6) (1 4 .7 2 ) (1 9 .7 1 ) (1 7 .1 8 ) (1 1 .9 8 ) (5 .7 2 ) (2 .5 1 ) (1 9 .8 1 ) (1 7 .3 0 )  (2 9 .7 4 ) (1 5 .7 6 )
pms 11.77 24.57 29 .23 2 4 .0 3 2 2 .4 0 1 2 .2 6 13 .15  21 .05 11.18 14.41
(N =16) (8 .7 9 ) (2 5 .1 6 ) (2 5 .1 5 ) (1 8 .5 7 ) (1 5 .5 4 ) (1 7 .5 6 ) (2 1 .9 4 )  (2 3 .4 8 ) (1 0 .3 8 ) (1 6 .4 0 )
unsure 10.69 14.49 2 6 .1 4 2 1 .9 8 18 .33 7 .59 1 0 .68  14 .64 12.38 1 1 .3 2
(N =12) (6 .5 4 ) (1 2 .7 1 ) (2 4 .7 3 ) (1 6 .4 0 ) (8 .8 3 ) (1 7 .3 9 ) (1 6 .0 5 ) (1 3 .4 9 )  (1 1 .1 6 ) (9 .6 8 )
Phase 15.15 22.25 2 7 .2 0 2 6 .1 8 9 .9 4 1 2 .2 6  15.38 16.71
Means (1 6 .5 6 ) (1 8 .5 7 ) (2 2 .1 2 ) (2 0 .1 2 ) (1 7 .1 0 ) (1 5 .9 5 )  (1 8 .6 8 )(2 4 .7 8 )
Note. Phase 1 =  menstrual; Phase 2 =  postmenstruai; Phase 3 = intermenstrual; Phase 4  
premenstrual.
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main effect for phase, F(6, 43 2 ) = 5.36, p < .001 (see Table 6). ANOVAs 
revealed a significant phase effect for both positive affect variability, F(3, 216) 
= 8.44, B < .001, and negative affect variability, F(3, 216) = 4.49, p < 025.
The phase effect for positive affect variability proved to be almost identical to 
that illustrated in Figure 1 for mean positive affect variability using the three 
groups of women.
Familv History of Mental Illness. The next analysis explored whether the 
inclusion of a diagnosed or suspected family history of mental illness variable 
would reveal group differences in two 3 (group) X 2 (presence, absence of 
family history) X 4  (menstrual cycle phase) mixed MANOVAs. Means are listed 
in Appendix L. The pill group by family history variable interaction was not 
significant, F (4, 180) = 1.81, p  > .05, nor were any of the other main effect or 
interaction tests. F values are listed in Appendix M. The means for the 
MANOVA on variability scores are listed in Table 7. This MANOVA found only a 
main effect for menstrual cycle phase, F (6, 540) = 3.31, p < .01. As can be 
seen from the F values for positive affect and negative affect variability 
respectively (see Tables 8 and 9) there was a significant effect for phase for 
positive affect variability and a significant group X family history X phase 
interaction for negative affect variability. While the identical positive affect 
variability phase effect was reported in the main analyses (see Figure 1 ), two 
new differences were found for negative affect variability: (a) a significant




Multivariate Analysis of Variance for PMS (Affect Variability Scores)
Source E rro r F
PMS Group (PM)
Between Subjects 
4 144 0 .33
Pill Group (PG) 2 71 0 .43
PM X PG 4 144 1.19
Cycle Phase (CP)
Within Subjects 
6 4 3 2 5 .3 6  *
CP X PM 12 4 3 2 0 .9 3
CP X PG 6 4 3 2 0 .3 9
CP X PM X PG 12 4 3 2 1 .08
Note. *e < .0 5 .  < .01 .




Illness History, and Menstrual Cvcle Phase
Positive Affect Negative A ffect
Phase
Group 1 2 3 4 (group
mean)






(1 8 .6 6 )
2 3 .8 7
(1 7 .4 7 )
31 .59
(23 .49 )
2 6 .4 9
(2 4 .4 8 )
2 4 .6 6
(1 5 .5 0 )
12.18
(1 9 .0 9 )
12.50  1 7 .5 9  2 4 .4 6  
(14.81 ) ( 2 1 .6 9 ) (3 6 .7 7 )
16 .68
(1 8 .6 6 )
history
(N = 19)
1 8 .6 0
(2 2 .5 1 )
2 1 .28
(1 5 .9 9 )
23 .16
(1 7 .1 0 )
27.91
(2 0 .1 9 )
2 2 .7 4
(1 6 .0 8 )
9 .0 6
(1 6 .5 8 )
9 .78  8 .1 3  9 .5 0  
(9 .3 4 ) (9 .7 0 )  (1 1 .3 5 )
9 .15





(3 3 .6 5 )
24 .88
(2 1 .4 7 )
25 .10
(3 7 .1 3 )
2 4 .6 7
(2 2 .3 7 )
2 6 .6 0
(2 3 .0 9 )
20 .65
(2 4 .7 9 )
6.41 1 3 .9 5  2 5 .2 3  
(5 .8 2 ) (1 6 .6 2 )  (2 6 .4 0 )
16 .56




(1 5 .8 2 )
23 .8 2
(2 0 .8 9 )
20 .73
(1 4 .7 2 )
2 9 .5 6
(2 3 .5 3 )
2 2 .6 2
(1 3 .7 1 )
8 .62
(9 .9 5 )
16.83 1 8 .5 9  12.21  
(1 9 .6 4 ) (1 4 .8 5 )  (8 .1 3 )
14 .06





(8 .5 1 )
23 .59
(2 2 .0 1 )
28 .12
(24 .93 )
2 3 .1 6
(1 6 .2 2 )
2 1 .7 0
(1 2 .6 8 )
11 .86
(1 9 .3 5 )
16.15 1 8 .53  1 2 .0 6  
(2 2 .5 5 ) (2 1 .6 6 ) (1 1 .9 6 )
14.65




(1 0 .3 8 )
18 .54
(1 9 .0 1 )
24 .06
(2 1 .3 6 )
26.31
(1 7 .7 1 )
2 0 .0 7
(1 1 .3 5 )
4 .38
(6 .0 8 )
9.15 1 6 .4 7  1 8 .28  
(1 2 .2 3 X 1 4 .9 6 )  (2 1 .2 9 )
1 2 .07




(1 8 .3 8 )
2 2 .6 4  26 .54  
(1 8 .7 2 ) (22 .60 )
2 6 .2 0
(2 0 .4 5 )
10.68
(1 7 .1 6 )
12.31 15.61 16 .73  
(1 5 .8 0 ) (1 7 .9 6 ) (2 3 .6 0 )
Note. Phase 1 =  menstrual; Phase 2 = postmenstruai; Phase 3 =  intermenstrual; Phase 4  =  
prem enstrual.




Analysis of Variance for Familv History of Mental Illness (Positive Affect Variability Scores)
Source df F
Personal History Group (FH)
Between Subjects
1 0 .55
Pill Group (PG) 2 0 .4 6
FH X PG 2 0 .04
S within-group  
error 9 0 (9 0 2 .6 6 )
Cycle Phase (CP)
Within Subjects
3 4 .6 6  * *
CP X FH 3 1.21
CP X PG 6 0 .93
CP X FH X PG 6 0 .7 0
CP X S within- 
group error 2 7 0 (1 0 .5 9 )
Note. Values enclosed in parentheses represent mean square errors. 
S =  subjects.
*E  < .0 2 5 .  * *E  < .0 1 .




Analysis of Variance for Familv History of Mental Illness (Negative Affect Variability Scores)
Source F
Personal History Group (FH)
Between Subjects
1 1 .72
Pill Group (PG) 2 0 .17
FH XPG 2 0 .36
S within-group  




C P X F H 3 1.41
CP X PG 6 0 .6 6
CP X FH X PG 6 2.81 *
CP X S within- 
group error 2 7 0 (2 0 2 .7 8 )
Note. Values enclosed in parentheses represent mean square errors. 
S =  subjects.
< .0 2 5 . < .01.
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phase effect for women with a family history of mental illness, F (3, 117) = 
3.77, E < .025, and (b) a significant phase effect for the long-term user group, 
F (3, 96) = 3.37, B < .025.
Personal Historv of Mental Illness. The effects of a third factor, 
presence/absence of a suspected or diagnosed personal history of mental 
illness, was explored in two 3 (group) X 2 (presence, absence of personal 
history) X 4  (menstrual cycle phase) mixed MANOVAs. The mean affect scores 
are presented in Table 10. The only significant finding was a main effect for the 
personal history of mental illness variable, F (2, 89) = 3.58, p < .05 (see 
Appendix N for the MANOVA source table). There were no significant main 
effects or interactions for the mean positive affect scores (see Appendix 0 ), 
but a significant main effect for the personal history variable for the negative 
affect scores, F (1, 90) = 7,22, p < .025, was revealed (see Table 11). The 
women with a suspected or diagnosed history of mental illness experienced 
more negative affect than women without a suspected or diagnosed history of 
mental illness.
The mean variability scores for the variances MANOVA are presented in 
Table 12. The results of the MANOVA found only a significant main effect for 
phase, F (6, 540) = 2.57, p < .05 (see Appendix P). A group X personal history 
of mental illness X phase interaction was revealed for negative affect 
variability scores, F (6, 270) = 2.86, p < .025 (see Table 13). Further analyses




Mean Positive and Negative A ffect Scores as a Function of Pill-Use Group. Personal Mental Illness 
Historv.and Menstnjal Cvcle Phase
Positive A ffect Negative A ffect
Phase
Group 1 2 3 4 (group
mean)






(8 .3 1 )
13 .22
(7 .6 2 )
13 .39
(7 .3 8 )
1 4 .4 2
(7 .7 3 )
13 .55
(7 .2 7 )
3 .48
(3 .4 9 )
3 .6 0
(3 .3 3 )
4 .0 4
(4 .1 3 )
3.95
(3 .6 7 )
3 .7 7




(5 .7 0 )
14 .55
(5 .6 4 )
1 5 .69
(5 .2 2 )
1 3 .7 4
(6 .1 1 )
1 4 .68
(5 .1 4 )
10.01
(5 .9 6 )
9 .8 6
(7 .4 3 )
8 .18
(6 .6 0 )
8.86
(5 .6 2 )
9 .2 3





(7 .9 4 )
14 .22
(8 .4 9 )
1 4 .00
(1 0 .1 1 )
1 2 .6 0
(8 .0 0 )
1 3 .56
(7 .7 0 )
6 .63
(7 .6 3 )
6 .0 8
(6 .7 4 )
6 .60
(7 .2 8 )
6 .46
(6 .4 6 )
6 .4 4




(4 .6 8 )
16 .59
(3 .9 9 )
1 5 .05
(5 .1 0 )
1 6 .0 6
(5 .5 5 )
1 5 .9 7
(4 .6 5 )
7 .88
(3 .8 7 )
9 .5 0
(6 .0 8 )
8 .9 7









(7 .7 6 )
13.31
(5 .7 6 )
13 .78
(5 .8 4 )
13.91
(5 .6 4 )
1 3 .63
(5 .6 8 )
5 .49
(5 .8 5 )
5 .08
(4 .7 1 )
5 .0 0
(3 .8 6 )
4.62
(3 .6 2 )
5 .05




(6 .1 9 )
9 .35
(6 .6 0 )
9.61
(5 .6 6 )
1 0 .2 9
(5 .2 3 )
9 .5 2
(5 .4 7 )
5 .92
(6 .9 3 )
6 .43
(6 .0 6 )
8 .08
(5 .6 7 )
6 .44
(5 .4 0 )
6 .7 2




(7 .5 3 )
13 .37
(6 .8 3 )
13.61
(6 .9 3 )
1 3 .7 2
(6 .7 4 )
5 .60
(5 .6 7 )
5 .5 7  5 .69  
(5 .4 3 )  (5 .1 3 )
5 .40
(4 .6 7 )
Note. Phase 1 =  menstmal; Phase 2 =  postmenstmal; Phase 3 =  intemienstrual; Phase 4  = 
prem enstrual.




Analysis of Variance for Personal Historv of Mental Illness (Mean Negative Affect Scores)
Source df F
Personal History Group (PH)
Between Subjects
1 7 .2 2  * *
Pill Group (PG) 2 0 .54
PH X PG 2 1.47
S within-group 




CP X PH 3 0.61
CP X PG 6 0.64
CP X PH X PG 6 1.56
CP X S w ithin- 
group error 2 70 (6 .3 2 )
Note. Values enclosed in parentheses represent mean square errors. 
S =  subjects.
*E  < 0 2 5 . * *E  < .0 1 .




Illness Historv. and Menstrual Cvcle Phase
Positive Affect Negative A ffect
Phase
Group 1 2 3 4 (group
mean)






(2 0 .4 0 )
2 2 .02




(2 3 .9 0 )
2 3 .8 3
(1 5 .7 4 )
7.01
(9 .4 9 )
8 .92  1 4 ,2 7  15.55  
(1 0 .3 7 ) (1 9 .4 4 )  (2 7 .2 8 )
11 .4 4




(2 0 .2 5 )
2 5 .1 2
(1 9 .0 4 )
25.29
(1 9 .4 2 )
2 6 .10
(1 8 .6 5 )
2 3 .8 9
(1 5 .9 0 )
2 2 .7 7
(3 0 .2 1 )
18 .86  1 1 .50  26 .15  
(1 6 .6 3 ) (1 3 .8 4 )  (3 6 .1 7 )
1 9 .82





(1 8 .9 7 )
2 3 .8 4




(2 3 .4 0 )
2 4 .0 9
(1 6 .1 8 )
9.01
(7 .6 3 )
10 .28  16 .14  16 .50  
(1 3 .7 2 ) (1 6 .3 4 )(2 1 .0 0 )
1 2 .98
(9 .6 1 )
history
(N =5)
2 8 .8 8
(3 8 .0 4 )
2 5 .2 6
(2 8 .0 2 )
20 .89
(2 0 .2 0 )
23 .65
(2 2 .1 0 )
2 4 .6 7
(2 2 .7 8 )
24 .5 5
(3 0 .3 4 )
17 .97  17 .97  2 0 .15  
(2 1 .4 5 ) (1 3 .9 6 )(1 2 .0 0 )
2 0 .1 6





(9 .1 1 )
2 2 .9 0
(2 0 .1 6 )
26 .74
(2 6 .2 8 )
2 2 .54
(1 6 .6 9 )
2 1 .0 6
(1 3 .0 4 )
1 0 .10
(1 8 .0 6 )
13.31 13.75  11.71  
(2 0 .6 8 ) (1 6 .1 9 ) (1 0 .9 0 )
1 2 .22




(9 .6 8 )
17 .64
(2 3 .5 9 )
26.01
(1 0 .5 0 )
30 .28
(1 5 .9 6 )
2 1 .1 2
(8 .7 2 )
5 .43
(3 .8 0 )
14.01 30.71 2 3 .3 0  
(1 5 .4 1 ) (2 3 .2 6 )(2 6 .2 3 )
18 .3 6




(1 8 .3 8 )
1 2 2 .6 4  26 .54  
(1 8 .7 2 ) (2 2 .6 0 )
2 6 .20
(2 0 .4 5 )
10 .68
(1 7 .1 6 )
12.31 15.61 16.73  
(1 5 .8 0 ) (1 7 .9 6 )(2 3 .6 0 )
Note. Phase 1 =  menstrual; Phase 2 = postmenstruai; Phase 3 = intermenstrual; Phase 4  =  
premenstrual.
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Table 13
Analysis of Variance for Personal Historv o f Mental Illness 




Personal History Group (PH)
Between Subjects
1 4 .1 7
Pill Group (PG) 2 0 .0 4
PH X PG 2 0 .04
S within-group 




CP X PH 3 0 .25
CP X PG 6 1.92
CP X PH X PG 6 2 .8 6  *
CP X S within- 
group error 270 (2 0 3 .0 7 )
Note. Values enclosed in parentheses represent mean square errors. 
S =  subjects.
*E  < .0 2 5 . **E  < .01.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
58
identified: (a) a phase effect for women without a personal history of mental 
illness, F (3, 207) = 3.26, Q < .025; (b) a phase effect for the long-time user 
group, F (3, 96) = 6.31, g  < .01 ; and (c) a personal history X phase interaction 
for the long-term user group, F (3 , 96) = 4 .11, g  < .01 (see Appendix P). 
Analvsis of Somatic Subscales
Originally the total somatic symptom mean and variability scores were 
calculated for each phase to determine whether variance attributable to 
somatic effects could account for any group effects for the positive and 
negative affect MANOVAs. Despite there being no group differences found for 
positive or negative affect mean or variability scores across the cycle for the 
main analyses, a 3 (group) X 4  (menstrual cycle phase) mixed ANOVA was 
performed first, on mean somatic scores and second, on mean somatic 
variability scores. The mean somatic scale scores and mean variability somatic 
scale scores for each group and cycle phase are found in Table 14 While the 
ANOVA on mean scores did not find a significant main effect for group,
F (2, 93 ) = 2.27, g > .05; there was a significant phase effect, F (3, 279) =
1 5.92, g < .001 ; and no group X phase interaction, F (6, 279) = 0.84, g > .05. 
The women experienced significantly more somatic symptoms during the 
menstrual phase than the other three phases, gs (279) = 0 .14, 0.14, 0 .07, 
gs < .0 1 ; and significantly more somatic symptoms in the premenstrual phase 
than the postmenstruai and intermenstrual phases, gs(279) = 0.07, 0.07,




Mean Total Somatic Svmptom Scores and Mean Total Somatic Svrnotom Variabilitv 
Scores for the Three Groups Across the Four Phases of the Menstrual Cvcle
Mean Somatic Symptom Scores Mean Somatic Symptom Variability Scores
Phase
Group 1 2 3 4 (group
mean)





(0 .3 5 )
0 .28
(0 .3 1 )
0 .28
(0 .2 8 )
0 .3 5
(0 .3 5 )
0 .34
(0 .3 2 )
0 .42
(0 .4 2 )
0 .2 4
(0 .2 6 )
0 .3 3
(0 .3 6 )
0 .43
(0 .6 3 )
0 .36
(0 .4 2 )
First Time  
Users
0 .5 4
(0 .3 9 )
0 .45
(0 .4 5 )
0 .4 6
(0 .4 2 )
0 .5 6
(0 .4 5 )
0 .5 0
(0 .4 3 )
0 .52
(0 .4 8 )
0 .33
(0 .3 4 )
0 .3 3
(0 .2 7 )
0 .48
(0 .4 0 )
0.42




(0 .3 0 )
0 .29
(0 .2 0 )
0.31
(0 .1 6 )
0 .3 5
(0 .2 2 )
0 .35
(0 .2 2 )
0.28
(0 .2 3 )
0 .27
(0 .3 3 )
0 .4 0
(0 .3 2 )
0 .4 0
(0 .3 5 )
0 .34




(0 .3 4 )
0 .32
(0 .3 1 )
0 .32
(0 .2 8 )
0 .3 9
(0 .3 4 )
0 .39
(0 .3 8 )
0 .27
(0 .3 0 )
0 .3 5
(0 .3 3 )
0 .43
(0 .5 0 )
Note. Phase 1 =  menstmal; Phase 2 = postmenstmal; Phase 3 = intermenstmal; Phase 4  =  
prem enstrual.
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Menstrual Cycle Phase
Figure 4. Mean total somatic symptom scores for all women across the 
menstrual cycle. The women reported significantly more somatic symptoms 
during the menstrual phase than during the other three phases and during the 
premenstrual phase than the postmenstruai and intermenstrual phases. 
Vertical lines depict standard errors of the mean.









0 .4 0 -
i f
I
0 .3 5 -
0 .3 0 -
0 .25
menstrual postmenstruai intermenstrual premenstrual
Menstrual Cycle Phase
Figure 5. Mean total somatic symptom variability scores for all women across 
the menstrual cycle. The women reported significantly more variability in 
somatic symptoms during the premenstrual and menstrual phases than the 
postmenstruai phase. Vertical lines depict standard errors of the mean.
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QS < .01. The phase effect is illustrated in Figure 4. The analysis of the 
somatic variability scores found results similar to those listed above: no group 
effect, F (2 , 93 ) = 0.46, g > .05; a phase effect, F (3, 279) = 4 .17 , g  < .01 ; and 
no group X phase interaction, F (6, 179) = 1.28, g > .05. Figure 5 shows that 
the women experienced more variability in somatic symptoms during the 
premenstrual and menstrual phases than they did during the postmenstruai 
phase, g (2 7 9 ) = 0 .16 and 0.13, gs < .01 and .025 respectively.
Discussion 
Summary of the Findings 
Main Hypotheses. Neither of the main hypotheses were supported in the 
present study. No significant group differences were found between first-time, 
long-time, and never users of OCs on negative or positive affect mean or 
variability scores.
Exploration of Pill Tvoe. Triphasic OC users had significantly more 
positive affect variability during the intermenstrual phase than the menstrual 
phase, the monophasic users did not. Furthermore, the first-time monophasic 
users experienced significantly less stability in positive affect during the 
menstrual phase than first-time triphasic users, long-time monophasic users, 
and long-time triphasic users.
Further Exploration of Group Differences. Further division of the three pill 
user groups by suspected or diagnosed PMS, family history of mental illness, or
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personal history of mental illness suggested that neither OC use or duration of 
use affects one's experience of overall positive or negative affect. However, a 
suspected or diagnosed family or personal history of mental illness does seem 
to differentially affect the stability of negative affect across the three groups 
and across the cycle. This interaction was a weak one, however.
Phase Differences in Affect Scores. There were no differences in mean 
negative or positive affect scores across the phases of the menstrual cycle. 
However, the women did experience more stability in positive affect during the 
menstrual phase than during the other three phases.
Somatic Svmotoms. None of the three groups differed significantly in 
their overall experience of mean somatic symptoms or variability of somatic 
symptoms. With regards to simple phase effects, women experienced more 
somatic symptoms during the menstrual phase than during the other three 
phases, and during the premenstrual phase than during the postmenstrual and 
intermenstrual phases. They also reported more somatic symptom variability 
during both the premenstrual and menstrual phases than during the 
postmenstrual phase.
Discussion of Results 
No Group Differences in Affect
The present data were not congruent with the hypothesis that first-time 
OC users experience higher negative affect and lower positive affect than long-
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time users and never-users. No differences in positive or negative affect were 
found between the three groups of women over the entire menstrual cycle or 
at any specific phase of the cycle. For positive affect, the lack of group 
differences between non-users and OC users is consistent with a majority of 
studies done (e.g., Boyle & Grant, 1992; Marriott & Faragher, 1968; Moos,
1968; Silbergeld, Brast, & Noble, 1971) yet inconsistent with a few others (e.g., 
Almagor & Ben-Porath, 1991; McFariane, Martin, & Williams, 1988). For 
negative affect, the above findings were in line with some studies (Almagor & 
Ben-Porath, 1991 ; Marriott & Faragher, 1986; Paige, 1971) but not with 
others (Boyle & Grant, 1992; Moos, 1968; Walker & Bancroft, 1990; Wilcoxon 
et al., 1976). It is noteworthy that while previous studies have investigated 
either early, middle, or long-time use of OCs, the present study was the first to 
compare a group of first-time and long-time users. Obviously, the results of 
the present study alone cannot completely clear up controversy regarding the 
existence of group differences.
Three arguments could be made against the validity of the present 
findings. First, while the sample size is one of the largest in this area of 
research to date, a larger sample may be required to provide enough 
statistical power to detect group differences. This argument can be countered 
simply be looking at the means and the F values in the analysis. For positive 
affect, the means were not even in the predicted direction. However, for
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negative affect, all F values were well below one which suggests that simply 
increasing the sample size will not lead to significant differences. Second, the 
ratings of positive and negative affect had large between-subject variation or 
variance. Third, as pointed out by Walker and Bancroft (1 9 9 0 ), a failure to find 
group differences may be due to the failure to distinguish between monophasic 
and triphasic preparation users. However, when this distinction was made, 
admittedly with smaller numbers in each cell, no group differences were found. 
The above three arguments do not seem to pose a great threat to the validity 
of the present findings.
The results suggest three implications. First, it is difficult in the face of 
these findings to sustain the view that taking OCs leads to a common decrease 
or increase in positive or negative affect for all women. If some women do 
experience positive or negative affect change as a result o f OC use, a third 
mediating or moderating variable must play a role. Second, the results do not 
suggest that the hormones in OCs lead to different psychoneuroendocrine 
actions on affect/mood during early or late use of OCs. Finally, no support 
was found for the role of the survivor effect as an artifactual confound. Since 
no group differences in affect were found between first-time and long-time 
users, this suggested that even if the survivor effect does exist for some 
groups of women, it is not large enough to explain the failure of late-use studies 
to find group differences in negative or positive affect.
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No Group Differences in Affect Variability
The results of the present study did not support the hypothesis that 
long-time OC users experience more stability of negative affect and positive 
affect than never-users and first-time users. None of the three groups differed 
in their experience of positive or negative affect variability. No previous studies 
have compared positive affect variability in OC users and non-users. McFariane 
et al. ( 1986) came the closest to examining positive affect variability by 
assessing "mood stability". They did not find any group differences. For 
negative affect variability, the present findings were not in line with previous 
studies comparing OC users and non-users (Paige, 1972; Rouse, 1978; Sutker 
et al., 1983; Warner & Bancroft, 1988). These studies indicated that OC users 
had more stable levels of negative affect either across the menstrual cycle or 
within certain phases. The findings of the present study were not in line with 
those of the majority of previous studies.
The same sample size and large between-subject variances arguments 
outlined earlier could be presented as threats to the validity of the affect 
variability findings. However, the very low F value suggests that no significant 
differences in affect variability exist between the three groups of women. Two 
implications come from this finding. The first is simply that all women who take 
OCs may not experience a uniform increase or decrease in the stability of day- 
to-day positive or negative affect compared to never-users. Secondly, women
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just starting on OCs may not differ from long-time users as a whole on their 
mood lability or stability across the cycle or within certain phases. These 
findings are surprising in light of previous support for the OC mood-stabilizing 
hypothesis.
Pill Tvoe: Monoohasic and Triphasic Preparations
While triphasic OC users experienced more positive affect variability in the 
intermenstrual phase than in the menstrual phase, there were no significant 
phase differences for the monophasic users. This finding is similar to that of 
Warner and Bancroft (1988) yet contrary to Moos' (1 9 6 8 ) finding. Warner 
and Bancroft found that monophasic users showed less variation in well-being 
than triphasic users overall and that triphasic users had more variation during 
the menstrual phase than monophasic users.
The above finding could be interpreted in one or more of three possible 
ways: (a) a methodological artifact due to unequal days in the menstrual cycle 
phases, (b) an indirect pharmacological effect on mood stability, or (c) a direct 
pharmacological effect on mood stability.
It seems plausible that for a sample with high between-subject and within- 
subject variability, cycle phases which contain more days (the intermenstrual 
phase) would have larger variances than phases which contain less days (the 
menstrual phase) since the longer phases contain more scores. Therefore the 
above finding could be an artifact of the length of the phase. This
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interpretation is supported by significant correlations between the number of 
days in the menstrual and intermenstrual phases and the positive affect 
variability scores for these phases, rs = .23 and .25, g < .05.
Four lines of evidence suggest that differences in phase length cannot 
entirely account for the finding. First, while the above correlations are 
significant, they are small and account for little variance (5.8% ). Second, visual 
inspection of mean positive affect variability scores for the three groups also 
indicates that the first-time users menstrual and intermenstrual phase scores 
were almost identical. Third, the women in this study experienced more 
somatic symptom variability during the menstrual phase than the 
postmenstrual phase (which contains more days). Finally, it can be argued 
that if the number of days in the phase accounted entirely for this finding, then 
there would have been similar phase differences for the monophasic users here, 
and for both of these groups of women on negative affect variability. These 
differences were not found, which suggests that differences in phase length 
cannot entirely account for the positive affect stability differences between 
monophasic and triphasic users.
The likelihood that phase differences in positive affect variability for the 
triphasic users could be the result of different somatic side effects from the 
monophasic and triphasic preparations is low. A comparison of monophasic 
and triphasic users on both total mean somatic scores and total mean
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variability somatic scores across the phases of the cycle did not find any group 
effects or interactions. Since an OC type by menstrual cycle phase interaction 
was found for positive affect variability, the women's overall experience of 
somatic symptoms cannot entirely explain the positive affect variability group 
differences. However, this does not rule out individual somatic symptoms as 
contributing to positive affect variability differences between the two pill-types.
The final interpretation of the differences is a pharmacological effect of 
the OCs on positive affect variability. While monophasic OCs contain consistent 
levels of estrogen and progestin across the 21 days, the triphasic OCs change 
the levels of progestin (and sometimes estrogen) three times during the 21 
days. The simple act of switching dosages may increase positive affect 
variability across the cycle. However, for triphasic users the progestin dosage 
is usually one-half to two times higher during the intermenstrual phase than the 
menstrual phase. Increased positive affect variability may be related to 
increased progestin. However, future research is needed before an exact 
pharmacological mechanism could be proposed. Both the type and dosage of 
the progestin would need to be controlled in a comparison of the mono- and tri­
phasic users.
While this finding must be replicated before any conclusions can be 
drawn, it does suggest the possibility of a pharmacological effect on positive 
affect variability. If the finding is replicated, a practical application might be
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that triphasic OC users complaining of mood lability may experience more 
positive affect stability on a monophasic preparation.
The comparison of mono- and tri- phasic users resulted in a second 
finding. The first-time monophasic users experienced more positive affect 
variability than first-time triphasic users, long-time monophasic users, and long­
time triphasic users during the menstrual phase. No previous studies have 
compared first-time and long-time users of OCs in general or with further 
separation by the type of pill.
Before any conclusions could be drawn about the above finding, it was 
necessary to ensure equivalency of the groups on five variables: personal 
history of mental illness, family history of mental illness, mean and variability of 
somatic symptoms during the menstrual phase, number of cycles of OC use, 
and proportion of specific OC types taken. Since no group differences were 
found, none of these variables could account for the observed difference.
Keeping in mind the small samples used in this analysis, the finding 
suggests that the early use of monophasic OCs is associated with higher 
variability in positive affect during the menstrual phase than the early use of 
triphasics. This increased variability disappears after at least two years of 
taking OCs suggesting that the increased variability may reflect a greater 
withdrawal effect during the pill-free week for the monophasic than triphasic 
users. The monophasic women take a constant hormone dosage for 21 days
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which is then suddenly withdrawn while the triphasic users have had gradual 
changes in the dosage throughout the cycle. Perhaps adjustments occur over 
time to adapt to this sudden withdrawal of exogenous hormones. The 
underlying implication is that both differences in duration of OC use and OC type 
are associated with differences in positive affect variability. Furthermore, while 
the main analyses suggest that the survivor effect is not a valid explanation for 
the failure of "late use" studies to find differences between OC users and non­
users, the above findings suggest that for certain groups of women, the 
survivor effect may play a role. High variability In positive affect may cause 
first-time users to discontinue OC use.
Premenstrual Svndrome History
Whether or not a woman believed that she experienced PMS did not 
differentiate never and long-time users on positive or negative affect or affect 
variability scores. This analysis was done since some of the previous research 
in the area looked at non-users and OC users who experienced PMS (e.g., 
Bancroft & Rennie, 1993; Bancroft, Sanders, Warner, & Loudon, 1987; Walker,
1994; Walker & Bancroft, 1990). However, nobody seems to have compared 
long-time and never-users based on their PMS history.
The most likely explanation for the lack of group differences in affect is 
that no differences exist. However, two possible threats to the validity of this 
conclusion must be mentioned. First this analysis had low statistical power as
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the number of women in each cell of the design ranged from only 6 to 18. 
Second, while the measure of PMS had reliability, there was no evidence of 
validity. There was no indication from the affect phase means that those 
women who answered yes to the PMS question experienced more negative 
affect in the premenstrual phase or greater intermenstrual to premenstrual 
increases in negative affect than those who answered no. In light of the power 
and validity issues, PMS history cannot be completely excluded as a possible 
mediating or moderating variable in any effect of OCs on affect.
Familv Mental Illness History
The addition of a suspected or diagnosed family history of mental illness 
variable did not reveal any differences in general positive or negative affect or 
affect variability. No other studies on positive or negative affect have 
investigated family history as a moderating variable. Some studies even 
excluded women who had a positive family history of mental illness (e.g., 
Silbergeld, Brast, & Noble, 1971). The only study to investigate the possible 
genetic influence of OC related changes in affect was a large scale twin study 
which concluded that OC-related depression (and irritability to a lesser extent) 
was clearly influenced by genetic factors and not by individual-specific 
environmental factors (Kendler, Martin, Heath, Handelsman, & Eaves, 1988).
Since the present analysis was exploratory, it seems important to 
mention that although post-hoc tests did not find differences between means, a
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significant weak interaction between the family history variable, menstrual cycle 
phase, and pill-use group was found for negative affect variability. Considering 
the small ns in each cell, and the fact that this was the only variable to produce 
significant (although weak) group differences for negative affect variability, 
family history of mental illness merits further exploration.
Personal Mental Illness History
First-time, long-time, or neyer users of OCs with a suspected or 
diagnosed personal history of mental illness do not seem to haye different 
experiences of negatiye or positiye affect or affect stability. No preyious 
studies have explored this relationship and it is not uncommon for studies to 
have excluded women with a personal mental illness history (e.g., Silbergeld, 
Brast, & Noble, 1971 ; Walker, 1994). However, some early studies examining 
diagnosable mood disorders as opposed to affect found that the relationship 
between OCs and depressive mood change was most strongly found in women 
who already had a predisposition to be depressed (e.g., Moller, 1981; Winston, 
1973).
As with the family history variable, a weak interaction between personal 
history, pill-use group, and menstrual cycle phase was found for negative affect 
variability. This interaction is again only being mentioned as it deserves further 
consideration since this study was the first to explore it. Although the number 
of women per cell in the analysis ranges from 5 to 34, the reliability (given
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earlier) of the personal history categorization seems quite good. There was no 
measure of validity for the categorization. This exploratory examination of 
personal mental illness history suggests that further exploration may be 
warranted.
Positive Affect Variabilitv Phase Effect
Significant differences in positive affect variability were found between 
the phases of the menstrual cycle. The womens ratings of positive affect were 
more stable during the menstrual phase than during the other three phases. 
This study was the first to examine positive affect variability across the 
menstrual cycle. Other studies have found phase effects for negative affect or 
mood (Boyle & Grant, 1992; Silbergeld, Brast, & Noble, 1971 ; Walker &
Bancroft, 1990). These studies found that negative affect was highest 
menstrually or premenstrually.
As was noted in the section on monophasic and triphasic preparation 
comparisons, the present phase effect could be interpreted in one or more of 
the following ways: (a) a methodological artifact of the number of days in the 
menstrual cycle phases, (b) a secondary effect of somatic symptoms on 
positive affect variability, or (c) a psychoneuroendocrine difference between 
phases of the cycle.
As outlined earlier, the number of days in each menstrual cycle phase 
cannot account for all of the variation in the positive affect variability scores
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across phases. With regards to somatic symptoms during the menstrual 
phase, there is no relationship between positive affect variability and the 
experience of somatic symptoms (r = -.05, g  > .05). However, there is a 
positive correlation between positive affect variability and somatic symptom 
variability (r = .25, g < .05). These two coefficients suggest that neither the 
experience of somatic symptoms or somatic variability can account for the 
phase effect. The nil and small contribution of the above two interpretations 
suggests that an internal psychoneuroendocrine mechanism may cause women 
to experience more stability of positive affect while they are menstruating.
Since both progesterone and estrogen levels are low during this period for both 
OC users and non-users perhaps these hormones play some sort of inhibitory 
role in the regulation of positive affect stability.
While it is possible that all three of the above interpretations contributed 
to the observed phase effect, further research is required before the 
psychoneuroendocrine explanation can be considered.
Somatic Svmotom Phase Effect
No group experienced a different intensity of somatic symptoms than 
any other. The women did, however, experience more intense somatic 
symptoms during the menstrual phase, followed by the premenstrual phase. 
More physical symptoms were experienced during these two phases than either 
of the other two. The lack of group differences is not congruent with previous
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studies (e.g., Bancroft & Rennie, 1993; Moos, 1968). Hoewever, the phase 
effects are congruent with previous research (Boyle & Grant, 1992; Marriott & 
Faragher, 1986; Silbergeld, Brast, & Noble, 1971 ; Walker & Bancroft, 1990; 
Wilcoxon et al., 1976). These somatic symptom phase effects seem to be a 
reliable finding.
While the women did not experience group differences in somatic 
symptom variability, there was a phase effect for the women as a whole. 
Compared to the postmenstrual phase, there was greater day-to-day 
instability of somatic symptoms in the premenstrual and menstrual phases.
This was the first study to specifically examine somatic symptom variability 
The phase effect findings seem straightforward and likely reflect the 
increases in pain and water retention which women commonly report 
experiencing in the days leading up to and during menstruation. Failure to find 
group differences in somatic symptoms, especially between first-time users and 
the other groups, could again be a function of the large between subject 
variation. Since physical side effects are common in the early use of OCs, it 
seems suspect that no group differences were found.
Studv Limitations and Future Research
Overall, the design of the present study was quite sound. One strength 
was the repeated-measure nature of the design, comparing each woman 
across the phases. This allows some confidence in the findings especially
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considering the fact that each mean score for each woman was based on a 
mean of 7 .68  observations.
Four aspects of the design could be improved upon. First, a larger 
sample would increase the statistical power of the design. Second, stricter 
subject selection criteria regarding relationship status would provide a more 
uniform sample and control for this possible confound. Third, the number of 
days in each menstrual phase should be equivalent in any study investigating 
affect variability. While some information will be lost by restricting the number 
of sampling days for some phases, the possibility of a methodological confound 
will be removed. Finally, the identification of a covariate for OC-related affect 
effects would help to reduce the high between-subject variation which could be 
obscuring any group differences. Other than larger sample sizes, these 
limitations of the design were not foreseen.
Future research should explore how OC type (monophasics and 
triphasics), family mental illness history, and personal mental illness history 
combine with duration of OC use or non-use to differentially effect positive and 
negative affect variability across the menstrual cycle phases. In particular, the 
monophasic/triphasic preparation user differences need to be replicated. An 
excellent experiment would involve a 2 (OC-type) X 2 (duration of OC use) X 4 
(triphasic OC cycle phase) design with the inclusion of users of monophasic and 
triphasic preparations who differ only by the dosage of the progesterone
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across the triphasic cycle. Two possible comparisons are: Cyclen versus Tri- 
Cyclen users; and Ortho 0 .5 /3 5 , Ortho 1 /3 5 , Brevicon 0 .5 /3 5 , and Brevicon 
1 /3 5  users versus Synphasic, Ortho 10 /11 , and Ortho 7 /7 /7  users. Min-Ovral 
could also be compared with Marvelon and Ortho-Cept to examine the effects 
of progestin type. The critical dependent variable would be positive affect 
variability. Salivary measures of estrogen and progesterone (e.g.. Mead & 
Hampson, 1996) would be an excellent addition to any future study. Future 
studies could also include valid and reliable measures of PMS, family mental 
illness history, and personal mental illness history since the present study, which 
used only simple unvalidated measures, found that the main effects and 
interactions approached significance.
In summary, the present study did not find any group differences in 
positive or negative affect or affect variability between first-time, long-time, 
and never-users of OCs. This finding did not support the notion of the survivor 
effect as an artifactual confound. However, the results of the comparison of 
monophasic and triphasic first-time and long-time OC users suggested that the 
survivor effect may account for differences in positive affect variability between 
early and late users of OCs for certain groups of women. The exploratory 
comparison of monophasic and triphasic first-time and long-time users found 
that between menstrual cycle phases, triphasic users experienced more 
variability in positive affect than did monophasic users. Furthermore, during the
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menstrual phase, the monophasic first-time users experienced more positive 
affect variability than the other three groups. Finally, while PMS history did not 
seem to differentially effect affect or affect variability for never, first-time, and 
long-time OC users, the presence /absence of family and personal mental illness 
history deserves further exploration.
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Monoohasic and Triphasic Combinations






















Initial General Information Questionnaire 
Please answer the following questions as honestly as you can. All answers will be kept 
anonymous and confidential.
1 ) Age:___
Years of Education (years from grade 1 to 13 + college + university):___________
Weight____________ (pounds) or____________ (kg)
Height____________ (feet & inches) or______________(cm)
2) List the types and names (as best you can remember) of all medications that you
are currently taking (including oral contraceptives) and the number of months 
that you have been taking them. Include any medications you will be starting 
soon.
Medication Number of nxmths of use
Please list any medical conditions which you have been diagnosed with (e.g., 
hypothyroidism, cancer, diabetes etc.).
3 ) a) Check the box which best explains your current romantic situation;
[ ] married or living with partner [ ] more than one steady partner
[ ] one steady partner but living apart [ ] no steady partner
[ ] other (please specify):___________
b) If you are currently in a steady relationship, how long have you and your 
partner been together (in years and months)?________years and_____ months
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c) Rate your happiness with the current romantic situation you are in,
regardless of whether you have no partner, a number of different partners, or
one steady partner:
extremely extremely
happy or satisfied unhappy or dissatisfied
0 1 2  3 4
4 ) Check the box of any disorder that you have been treated for, hospitalized for, or 
diagnosed with:
[ ] depression [ ] panic attacks [ ] other____________
[ ] bipolar disorder [ ] eating disorder
[ ] anxiety disorder [ ] schizophrenia
Do you feel or think that you may have some type of problem with mood, anxiety, 
or something else that you have never been diagnosed with or received treatment 
for? Please describe briefly what you believe to be the problem and why you 
believe this:
Check the box of any disorder that any family member has been treated for, 
hospitalized for, or diagnosed with and include the relationship of that family 
member to you on the line following the disorder (ie., mother, uncle, sister, 
grandfather):
[ ] depression____________  [ ] panic attacks____________  [ ] other_
[ ] bipolar disorder. 
[ ] anxiety disorder.
[ ] eating disorder. 
[ ] schizophrenia_
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Do you think or feel that any of your family members may have some type of 
problem with mood, anxiety, or something else, that they have never been 
diagnosed with or received treatment for? Please describe briefly what you 
believe to be the problem, why you believe this, and the relationship of this 
person to you (ie., mother, uncle, sister, grandfather); ______________________
5 ) Are you pregnant right now? [ ] yes [ ]no
Have you ever been pregnant before? [ ] yes [ ]no
If yes, how many times have you been pregnant?__________
If yes, how many children have you delivered?___________
Have you had a hysterectomy? [ ] yes [ ]no
At what age did you first start menstruating?______________
What is the average length of your menstrual cycle (in days)?________
Do you think that you may suffer from Premenstrual Syndrome (PMS)?
[ ]unsure [ ] yes [ ]no
6) a) Check the response that best describes your level of sexual activity:
[ ] I have never had sexual intercourse.
[ ] I have had sexual intercourse but am not presently sexually active.
[ ] I am presently sexually active.
b) Check the method(s) of birth control which you and your partner(s) are 
presently using or are about to start using within the next month:
[ ] condoms [ ] hysterectomy, tubal ligation, or vasectomy
[ ] intrauterine device (lUD) [ ] spermicidal jelly, cream, foam, suppository
[ ] sponge [ ] douche
[ ] diaphragm [ ] rhythm method
[ ] oral contraceptives(the pill) [ ] withdrawal
[ ] steroid implant (Norplant) [ ] injectable contraceptive (Depo-Provera)
[ ] none [ ] other (please specify):__________________
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c) Check all methods of birth control which you have used in the past
[ ] condoms [ ] surgical operation (hysterectomy/vasectomy)
[ ] intrauterine device (lUD) [ ] spermicidal jelly, cream, foam, suppository
[ ] sponge [ ] douche
[ ] diaphragm [ ] rhythm method
[ ] oral contraceptives(the pill)[ ] withdrawal
[ ] steroid implant (Norplant) [ ] injectable contraceptive (Depo-Provera)
[ ] none [ ] other (please specify):________________
d) How do you feel about pregnancy right now? Circle one number from 0 to 4.
I would be happy if I dont have strong feelings I would be devastated
I got pregnant about becoming pregnant if I became pregnant.
0 1 2  3 4
e) How often are you worried that your current or new method of birth control 
will fail and you will become pregnant? Circle one number from 0 to 4.
never sometimes always
0 1 2 3 4
f) How often you feel guilty or how often you think you would feel guilty about
using birth control to prevent pregnancy? Circle one number from 0 to 4.
never sometimes always
0 1 2 3 4
g) Circle the number under the response that is most comparable to the idea of 
finding out that you are pregnant today :
worst nightmare neutral wonderful dream
4 3 2 1 0
h) How reassured do you feel that your method of birth control will prevent you 
from getting pregnant? Circle one number.
extremely moderately not at all
0 1 2 3 4
i) Does the use of birth control cause you anxiety or stress because it goes
against your own moral standards (or those of someone close to you) since it can 
prevent the conception of a child? Circle one number from 0 to 4.
extremely moderately not at all
4 3 2 1 0
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j) Check off all items below which you think could be a possible side effect of using 
oral contraceptives (the pill):
] muscle stiffness 
] painful or tender breasts 
] skin blemish or disorder 
] swelling (breasts, abdomen) 
] negative mood effects 
] nausea, vomiting 
] difficulty concentrating 
] minor accidents 
] ringing in the ears 
] blind spots, fuzzy vision 
] weight loss 
] breast size decrease
] headache 
] improved mood 
] weight gain 
] dizziness, faintness 
] cramps
] feelings of suffocation 
] cold sweats 
] chest pains 








] heart pounding 
] distractable 
] hot flashes] poor motor coordination 
] breast size increase [ ] less cramps 
] clearer complexion (skin)
k) Imagine that each of the following symptoms occurred in you when you were 
taking oral contraceptives (the pill). Please rate how much distress you would 
feel about each. Use the following scale:
0 -this would not bother me at all
1 - Insert the number which best
2-this would be moderately bothersome describes your distress level in the
3 - box beside each item
4 -this would bother me a great deal
] muscle stiffness 
] painful or tender breasts 
] skin blemish or disorder 
] swelling (breasts, abdomen) 
] nausea, vomiting 
] blind spots, fuzzy vision 
] difficulty concentrating 
] ringing in the ears 
] weight loss 
] breast size decrease
] headache
] poor motor coordination 
] weight gain 
] dizziness, faintness 
] cramps
] feelings of suffocation 
] cold sweats 
] general aches and pains 
] breast size increase 
] clearer complexion (skin)
] numbness/tingling 
] hot flashes 
] chest pains 
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7 ) a) How often do you normally consume alcohol? Circle one number from 0 to 4.
never
0
once or twice 
a month 
1
once or twice 
a week 
2
three to four 





b) What is the average number of drinks you have when you drink? Circle one 
number.
none one to three four to seven 
0 1 2
eight to twelve more than 12 
3 4
c) How often do you use illegal drugs such as marijuana, hash, cocaine, LSD etc.? 
Circle one number.
once or twice once or twice three to four almost
never a month a week times a week every day
0 1 2  3 4
8 ) Below is a list of problems people sometimes have. Please read each one carefully, 
and check the box that best describes HOW MUCH THAT PROBLEM HAS DISTRESSED OR 
BOTHERED YOU DURING THE PAST 7 DAYS INCLUDING TODAY.
not at all
a little quite
bit moderately a bit extremely
1. Loss of sexual interest or pleasure....
2. Nervousness or shakiness inside.......
3. Feeling low in energy or slowed down.
4. Trembling..........................................
5. Thoughts of ending your life..............
6. Suddenly scared for no reason...........
7. Crying easily.....................................
8. Feeling fearful...................................
9. Feelings of being trapped or caught...
10. Heart pounding or racing.................
11. Blaming yourself for things.............
12. Feeling tense or keyed up................
13. Feeling lonely...................................
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14. Spells of terror or panic [ ]
15. Feeling blue [ ]
16. Feeling so restless
you couldnt sit still [ ]
17. Worrying too much about things [ ]
18. The feeling that something
bad is going to happen to you [ ]
19. Feeling no interest in things [ ]
20. Thoughts and images
of a frightening nature [ ]
21. Feeling hopeless about the future [ ]
22. Feeling everything is an effort [ ]
23. Feelings of worthlessness [ ]




Daily Rating Questionnaire 
Subject Number_________________
List the types and names of all medications which you are currently taking (including 
oral contraceptives) and the number of months which you have been taking them. Please 
look at your prescription bottle or package to write down the exact name and brand of 
each type of medication.
Medication name (look at bottle or package) Number of months of use
Attached to this sheet are a number of rating scales which you are to fill out every 
evening at the same time for the next 35 days starting today. Please place the 
date and your subject number at the top of each page and fill out each questionnaire on 
the day that it is meant to be filled out. If you forget to fill out the form for one day, then 
fill it out when you do remember but mark on the bottom that you filled it out on the next 
day. Dont forget to put your identification number on the top of each sheet Once you 
have completed all 35 days of the study, come to the final session at which time you will 
fill out one more questionnaire and receive either your bonus points if you are a first 
year psychology student or $10 if you are another volunteer.
Your final session date and time is:__________________________
Where?_______________________________
If for some reason you cannot make this final session then please call 
Kirsten Oinonen (343-8186) or Dr. Mazmanian (343-8257) to set up an altemate 
time. If you have any other questions about the study then do not hesitate to call. Just 
leave a message on the machine saying that you are a subject in her study and leave your 
phone number. Your call will be returned as soon as possible. Unless you object (and 
please make sure to tell the researcher today), the researcher will call you once in 
about two weeks to remind you to complete the daily rating forms. Remember that 
neither your name nor student number (if you are a first-year Psychology student) are 
connected with your subject number so your data will remain anonymous and 
confidential.





Below is a list of a number of words that describe different feelings and emotions. Read 
each item and then check the appropriate box. Indicate to what extent you have felt this 
way today.
very slightly quite





















The following is a list of common symptoms and feelings. For each item check the 
box for the category that best describes your experience today. Even if none of the 
categories is exactly correct, choose the one that best describes your experience. Please 
be sure to check one box for each item.
Present Present Present Present
None Mild Moderate Strong Severe
0 1 2 3 4
1. Muscle stiffness ........... .............[ ] [ ] [ ] [ ] [ ]







6. Skin blemish or disorder.....
7. Cold sweats ..........................
8. Anxiety ................................
9. Mood swings ........................
10. Cramps ...............................
11. Painful or tender breasts....
12. Nausea, vomiting ................
13. Crying .................................
14. Backache ............................
15. Swelling (breasts, abdomen)




20. Feeling sad or blue ............. .
21. General aches and pains ......
22. Restlessness ........................
23. Insomnia...............................
24. Poor school or work............
performance
25. Affectionate ........................
26. Feelings of suffocation ........
27. Forgetfulness........................
28. Take naps, stay in bed ........
29. Orderliness .........................
30. Chest pains .........................
31. Confusion.............................





32. Poor judgment .......................
33. Stay at home .........................
34. Excitement ............................
35. Ringing in the ears..................
36. Difficulty concentrating ........
37. Avoid social activities..............
38. Feelings of well-being ...........
39. Heart pounding ......................
40. Distractable ...........................
41. Decreased efficiency ..............
42. Bursts of energy, activity......
43. Numbness, tingling ................
44. Minor accidents ......................
45. Blind spots, fuzzy vision ........
46. Poor motor coordination..........
47. Increased appetite .................
48. Do you have your period








The following is a list of physical changes you may have observed in your body. For each 
item check the category that best describes your experience today. Even if none of the 
categories is exactly correct, choose the one that best describes your experience. Please 
be sure to check one box for each item.
Present Present Present Present
None Mild Moderate Stronq Severe
0 1 2 3 4
1. Weight loss .......................... .....[ ] [ ] [ ] [ ] [ ]
2. Breast size increase ............. .....[ ] [ ] [ ] [ ] [ J
3. Breast size decrease ............. .....[ ] [ ] [ ] [ ] [ ]
4. Clearer complexion (skin) .... .....[ ] [ ] [ ] [ ] [ ]





Final General Information Questionnaire
Please answer the following questions as honestly as you can. All answers will be kept 
anonymous and confidential.
1 ) Age:_
Years of Education (years from grade 1 to 13 + college + university):_____________
Weight____________ (pounds) or____________ (kg)
Height____________ (feet & inches) or______________(cm)
2) List the types and names (as best you can remember) of all medications that you are 
currently taking (including oral contraceptives) and the number of months that you 
have been taking them. Include any medications which you have been taking during 
the 35 days of this stucfy:
Medication Number of months of use
Please list any medical conditions which you have been diagnosed with (e.g., 
hypothyroidism, cancer, diabetes etc.).
3 ) a) Check the box which best explains your cunent romantic situation:
[ ] married or living with partner [ ] more than one steady partner
[ ] one steady partner but living apart [ ] no steady partner
[ ] other (please specify):___________
b) If you are currently in a steady relationship, how long have you and your 
partner been together (in years and months)?_________ years and_________months
c) Rate your happiness with the current situation you are in, regardless of 
whether you have no partner, a number of different partners, or one steady partner
extremely extremely
happy or satisfied unhappy or dissatisfied
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4 ) Check the box of any disorder that you have been treated for, hospitalized for, or 
diagnosed with:
[ ] depression [ ] panic attacks [ ] other___________
[ ] bipolar disorder [ ] eating disorder
[ ] anxiety disorder [ ] schizophrenia
Do you feel or think that you may have some type of problem with mood, anxiety, or 
something else that you have never been diagnosed with or received treatment for? 
Please describe briefly what you believe to be the problem and why you believe this:
Check the box of any disorder that any family member has been treated for, 
hospitalized for, or diagnosed with and include the relationship of that family member 
to you on the line following the disorder (ie., mother, uncle, sister, grandfather):
[ ] depression_____________ [ ] panic attacks____________  [ ] other________
[ ] bipolar disorder_________ [ ] eating disorder___________
[ ] anxiety disorder________ [ ] schizophrenia____________
Do you think or feel that any of your family members may have some type of problem 
with mood, anxiety, or something else, that they have never been diagnosed with or 
received treatment for? Please describe briefly what you believe to be the problem, 
why you believe this, and the relationship of this person to you (ie., mother, uncle, 
sister, grandfather):_________________________________________________
5 ) Are you pregnant right now? [ ] yes [ ]no
Have you ever been pregnant before? [ ] yes [ ]no
If yes, how many times have you been pregnant?__________
If yes, how many children have you delivered?____________
Have you had a hysterectomy? [ ] yes [ ]no
At what age did you first start menstruating?______________
What is the average length of your menstrual cycle (in days)?_________
Do you think that you may suffer from Premenstrual Syndrome (PMS)?
[ ] yes [ ]no
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6) a) Check the response that best describes your level of sexual activity:
[ ] I have never had sexual intercourse.
[ ] I have had sexual intercourse but not within the past 35 days.
[ ] I had sexual intercourse at least once during the past 35 days.
b) Check the method(s) of birth control which you and your partner(s) have been 
using during the 35 days of the study:
] condoms [ ] hysterectomy, tubal ligation, or vasectomy
] intrauterine device (lUD) [ ] spermicidal jelly, cream, foam, suppository
[ ] douche 
[ ] rhythm method 
[ ] withdrawal
[ ] injectable contraceptive (Depo-Provera)
[ ] other (please specify):________________
] sponge 
] diaphragm
] oral contraceptives(the pill) 
] steroid implant (Norplant)
] none
c) Check all methods of birth control which you have used in the past:
] condoms
] intrauterine device (lUD)
] sponge 
] diaphragm
] oral contraceptives(the pill) 
] steroid implant (Norplant)
] none
[ ] surgical operation(hysterectomy/vasectomy) 
[ ] spermicidal jelly, cream, foam, suppository 
[ ] douche 
[ ] rhythm method 
[ ] withdrawal
[ ] injectable contraceptive (Depo-Provera)
[ ] other (please specify):_________________
d) How do you feel about pregnancy right now? Circle one number from 0 to 4.
would be happy if 
got pregnant 
0 1
I dont have strong feelings 
about becoming pregnant 
2
I would be devastated 
if I became pregnant 
4
e) How often are you worried that your current or new method of birth control will 







f) How often do you feel gulty or how often do you think you would feel guilty about 
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g) Circle the number under the response that is most comparable to the idea of 
finding out that you are pregnant today :
worst nightmare neutral a wonderful dream
4 3 2 1 0
h) How reassured do you feel that your current or new method of birth control will 
prevent you from getting pregnant? Circle one number.
extremely moderately not at all
0 1 2 3 4
i) Does the use of birth control cause you anxiety or stress because it goes against 
your own moral standards (or those of someone close to you) since it can prevent the 
conception of a child? Circle one number from 0 to 4.
extremely moderately not at all
4 3 2 1 0
7 ) a) How often did you consume alcohol during the 35 days of this study? Circle one 
number from 0 to 4.
once or twice once or twice three to four almost
never a month a week times a week every day
0 1 2 3 4
b) What is the average number of drinks you had when you drank? Circle one 
number.
none one to three four to seven eight to twelve more than 12
0 1 2 3 4
c) How often did you use illegal drugs such as marijuana, hash, cocaine, LSD etc. 
during the 35 days of this study. Circle on number.
once or twice once or twice three to four almost
never a month a week times a week every day
0 1 2 3 4
THE REST OF THE QUESTIONS ARE FOR ORAL CONTRACEPTIVE USERS ONLY:
8 ) a) During the past 35 days, at what time of day did you most often take your pill:
no fixed early late early late early late
time moming morning afternoon afternoon evening evening 
0 1 2 3 4 5 6




b) Which statement best describes the way you took your pill during the past 35 
days:
[ ] at pretty much the exact same time everyday 
[ ] within 1 to 2 hours of the same time each day
[ ] within 3 to 4 hours of the same time each day
[ ] within 5 to 6 hours of the same time each day
[ ] I took the pill at any time of the day - whenever i remembered
c) During the past 35 days, how many times did you forget to take your pill and then 
take it the following day:
[ ] never [ ] two times [ ] other (specify):__________
[ ] one time [ ] three times
















a) Check off all items below which 
contraceptives (the pill):
[ ] muscle stiffness 
[ ] painful or tender breasts 
[ ] skin blemish or disorder 
[ ] swelling (breasts, abdomen)
[ ] negative mood effects 
[ ] nausea, vomiting 
[ ] difficulty concentrating 
[ ] minor accidents 
[ ] ringing in the ears 
[ ] blind spots, fuzzy vision 
[ ] weight loss 
[ ] breast size decrease
you found to be a side effect of using oral
[] headache 
] improved mood 
] weight gain 
] dizziness, faintness 
] cramps
] feelings of suffocation 
] cold sweats 
] chest pains 
] general aches and pains [
] poor motor coordination [
] breast size increase [








] heart pounding 
] distractable 
] hot flashes 
] less cramps
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b) If any of the following symptoms occurred in you when you were taking 
oral contraceptives (the pill) please rate how much distress you felt 
about each. Use the following scale:
0 -this would not bother me at all
1 -
2-this would be moderately bothersome
3 -
4 -this would bother me a great deal
[ ] muscle stiffness 
[ ] painful or tender breasts 
[ ] skin blemish or disorder 
[ ] swelling (breasts, abdomen) 
[ ] nausea, vomiting 
[ ] blind spots, fuzzy vision 
[ ] difficulty concentrating 
[ ] ringing in the ears 
[ ] weight loss 
[ ] breast size decrease
Insert the number which best describes 
your distress level in the box beside each- 
item
] headache [ ] numbness/tingling
] poor motor coordination [ ] hot flashes
] weight gain [ ] chest pains
] dizziness, faintness [ ] heart pounding
] cramps [ ] insomnia
] feelings of suffocation [ ] fatigue
] cold sweats [ ] backache
] general aches and pains [ ] less cramps 
] breast size increase 
] clearer complexion (skin)
11 ) What is the main reason that you started taking the oral contraceptive pill?
[ ] for birth control reasons (to prevent pregnancy)
[ ] medical reasons (please specify:__________________________________
[ ] other (please specify:__________________________________________
1 2 ) What is the main reason why you are presently taking the oral contraceptive pill? 
[ ] for birth control reasons (to prevent pregnancy)
[ ] medical reasons (please specify:________________________________________
[ ] other (please specify________________________________________________
13) How many different types/brands of oral contraceptives have you taken?
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Oral Contraceptives
108
14) Please list the names of all the oral contraceptive pills you have taken starting with the 
most recent type;
Name of Pill Months on Pill
_____________________________________________________ foresentlv taking)
15) If you have taken more than one brand of oral contraceptives, why did you switch pills? 
Please describe in detail.





This study is being conducted by Kirsten Oinonen and Dr. D. Mazmanian of the 
Department of Psychology at Lakehead University. The purpose of this study is to monitor 
daily changes in physical, psychological, and emotional variables in first-time-users, long- 
time-users, and never-users of oral contraceptives.
This study consists of three stages. In Stage 1 you will be asked to fill out a 
questionnaire at Lakehead University which will take approximately 20 minutes. Stage 2 
involves completing a short questionnaire each day for 35 days. Stage 3 involves the 
completion of another questionnaire at Lakehead University following the completion of 
Stage 2. Following stage 3, all introductory students will receive three points toward their 
final mark and the other participants will receive ten dollars. The questionnaires include 
personal questions about topics such as menstrual history, physical and psychological 
complaints, drug and alcohol use, attitudes, and present romantic relationships.
Participation in this experiment is voluntary and you may withdraw at any time 
without explanation and without penalty. All records of your participation will be kept in 
strict confidence and any reports of the study will not identify you as a participant. As per 
university requirements, all data will be stored for seven years by Dr. D. Mazmanian at 
Lakehead University and remain anonymous and confidential. There are no known physical 
or psychological risks associated with participating in this study.




If you have any questions or concerns regarding this study please contact Kirsten 
Oinonen (345-5396) or Dr. D. Mazmanian (343-8257).





The data you have contributed will be used to investigate the psychological effects of 
oral contraceptive use. Portions of this research constitute a Masters Thesis by Kirsten 
Oinonen. We are particularly interested in determining the relationship, if any, between 
mood and oral contraceptive use in women. The popularity of oral contraceptive use among 
women necessitates an awareness of all risks and benefits and an awareness of the 
predisposing conditions that may make some women more prone to these side effects. 
Research on side effects of the pill is important whether they are positive or negative and 
whether the cause is pharmacological or psychological. Women need scientific assessments 
of benefits and risks in order to make an informed choice about what type of contraceptive 
method or what type of pill is the best for them.
Please be assured that all of your responses are coded to conceal your identity on the 
questionnaires and that all data will remain anonymous. Below are listed some related 
references which might be of interest to those who would like further information on how 
oral contraceptives may affect mood. If you have any questions or concerns regarding this 
study, you may contact Kirsten Oinonen (345-5396) or Dr. Mazmanian (343-8257). If 
you would like information on the results of this study then please fill in your address on 
the attached mailing label and a summary will be sent to you at the end of this study.
If you are experiencing any difficulties with your mood for any reason, and if you 
would like to discuss these concems with someone, the following community resources are 
suggested: your family physician, Lakehead University Psychology Clinic (343-8441 ), 
Canadian Mental Health Association (345-5564), or the Lakehead University Student 
Health Services (343-8361) if you are a student.
Almagor, M., & Ben-Porath, Y. (1991). Mood changes during the menstrual cycle 
and their relation to the use of oral contraceptives. Journal of Psvchosomatic Research.
35. 721-728.
Bancroft, J., & Sartorius, N. (1990). The effects of oral contraceptives on well­
being and sexuality. Oxford reviews of reproductive bioloov. 12. 57-92.




Number of Univariate Outliers Corrected for in each Cell of the Positive and
Negative Affect MANOVAs
Positive Affect Negative Affect
Group 1 2 3
Phase
4 1 2 3 4
1 1 1 0
Mean Scores 
0 1 1 0 1
2 0 0 0 0 1 0 0 0
3 0 0 0 0 0 0 1 1
1 1 1 1
Variability Scores 
0 2 1 1 2
2 0 0 1 0 1 0 0 1
3 1 0 1 0 1 1 1 1





Pain Water Autonomic Control
Retention Arousal
Phase
Group 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Mean Scores
1 0 0 0 0 1 1 1 1  1 2 2 2 1 2 2 3
2 0 0 0 0 0 0 0 0 1 1 1 0 1 0 1 1
3 1 0 1 0 1 0 1 0  1 1 0 1 0 0 0 1
Variability Scores
1 0 1 1 1 1 1 1 1  1 1 1 1 2 2 1 1
2 0 0 0 0 0 O i l  1 1 0 0 0 1 0 1
3 0 1 1 0 1 0 1 0  1 1 0 1 0 1 1 1




Pearson Product-Moment Correlation Coefficients for the Four Somatic Variables
Mean Scores Variability Scores
pain water autonomic control pain water autonomic control 























Note, p = mean pain, w = mean water, aa = mean autonomic arousal, c = mean control, 
v.p = mean pain variability, v.w = mean water variability, v.aa = mean autonomic arousal 
variability, v.c = mean control variability.




Mean Positive and Negative A ffec t Scores as a Function of Pill-Use Group. 
PMS Group and Phase o f the Menstrual Cvcle
Positive A ffect Negative A ffect
Phase
Group 1 2 3 4 (group
mean)




(N = 18 )
1 3 .16
(8 .8 1 )
13.08
(8 .1 3 )
12 .90
(7 .0 6 )
15 .1 0
(7 .3 0 )
1 3 .56
(7 .1 9 )
3.79
(3 .8 6 )
3 .86
(3 .4 2 )
3 .6 7
(4 .1 5 )
4 .0 7
(3 .9 5 )
3 .85




(6 .3 0 )
12.58
(6 .4 2 )
13 .10
(6 .9 3 )
1 2 .18
(6 .1 3 )
12 .48
(6 .0 7 )
5.51
(6 .0 1 )
5 .0 7
(5 .0 0 )
5 .95
(4 .4 6 )
6 .19
(4 .6 7 )
5 .6 8




(8 .0 4 )
15.84
(6 .9 4 )
17.16
(6 .7 6 )
16 .55
(8 .9 5 )
16 .47
(7 .3 7 )
6 .32
(6 .4 4 )
7.11
(7 .4 2 )
5 .9 2
(5 .8 1 )
5 .75
(5 .8 9 )
6 .28





(3 .7 2 )
10.41
(4 .3 0 )
9 .78
(3 .6 3 )
1 1 .8 2
(3 .7 6 )
10 .65
(3 .1 1 )
6 .28
(8 .0 9 )
7 .05
(6 .6 1 )
6 .4 0
(7 .5 0 )
6 .10
(6 .5 8 )
6 .4 6




(8 .0 5 )
14.53
(6 .0 5 )
13.87
(6 .5 1 )
1 4 .79
(5 .8 4 )
14 .55
(6 .0 8 )
6 .09
(5 .5 5 )
5 .2 6
(4 .8 8 )
5 .7 2
(4 .0 6 )
4.91
(3 .8 8 )
5 .5 0




(7 .7 4 )
10.48
(6 .3 8 )
12.87
(6 .0 9 )
1 1 .37
(5 .9 8 )
11 .15
(6 .0 8 )
4 .58
(5 .9 0 )
4 .7 6
(4 .5 3 )
5 .4 0
(3 .3 3 )
4 .7 0
(3 .0 4 )
4 .8 6




(7 .6 8 )
13.03
(6 .7 4 )
13 .44
(6 .5 7 )
1 3 .8 0
(6 .6 7 )
5.25
(5 .4 6 )
5 .2 0
(5 .1 6 )
5 .3 2
(4 .8 4 )
5 .14
(4 .4 2 )
Note. Phase 1 =  menstrual; Phase 2 = pcstmenstruai; Phase 3 = intermenstruai; Phase 4  =  
prem enstrual.









Pill Group (PG) 2 71 0.94




CPXPM 12 432 0.90
CPXPG 6 432 0.14
CP X PM X PG 12 432 0.62
Note. < .05. **B < .01.




Mean Positive and Negative A ffect Scores as a Function of Pill-Use Group. Family Mental Illness
History, and Menstrual Cvcle Phase
Positive Affect Negative A ffect
Phase
Group 1 2 3 4 (group
mean)






(8 .0 6 )
12.81
(7 .5 2 )
12 .5 0
(7 .3 4 )
1 2 .7 9
(8 .0 4 )
12.29
(7 .2 7 )
5.05
(4 .9 5 )
4.71
(5 .0 5 )
5 .2 8
(4 .4 4 )
5 .24
(4 .2 1 )
5 .07




(6 .6 7 )
15 .50
(6 .2 6 )
15 .95
(5 .9 4 )
1 6 .2 7
(5 .7 9 )
15.93
(5 .5 3 )
5 .12
(5 .2 7 )
5 .72
(5 .7 4 )
4 .7 4
(5 .9 8 )
5 .02
(5 .3 6 )
5 .15





(5 .5 5 )
15.36
(7 .5 1 )
12.93
(9 .8 3 )
1 9 .9 2
(8 .3 2 )
13 .24
(6 .7 0 )
5.11
(2 .9 3 )
5 .07
(5 .0 2 )
6 .1 8
(4 .8 2 )
7 .18
(6 .1 9 )
5 .88




(7 .8 0 )
14 .60
(7 .7 1 )
15.27
(8 .3 6 )
1 4 .1 0
(7 .0 6 )
14.99
(7 .2 9 )
8 .32
(8 .2 4 )
8 .5 0
(7 .3 8 )
8 .0 8
(7 .4 0 )
6 .47
(5 .6 4 )
7 .84





(7 .8 8 )
14 .14
(5 .9 2 )
1 4 .3 0
(5 .9 0 )
1 4 .1 0
(5 .8 2 )
14.05
(5 .9 4 )
6 .27
(6 .3 2 )
5 .9 0
(5 .2 0 )
5 .7 7
(4 .3 3 )
5 .17
(3 .9 1 )
5 .78




(6 .9 6 )
9.53
(5 .4 6 )
10 .37
(5 .4 9 )
1 1 .3 8
(5 .2 6 )
10.42
(5 .0 6 )
4 .49
(5 .5 4 )
4 .5 9
(4 .7 3 )
5 .6 6
(4 .8 3 )
4 .85
(4 .5 1 )
4 .9 0




(7 .5 3 )
13.37
(6 .8 3 )
13.61
(6 .9 3 )
1 3 .7 2
(6 .7 4 )
5 .60
(5 .6 7 )
5 .57
(5 .4 3 )
5 .6 9
(5 .1 3 )
5 .40
(4 .6 7 )
Note. Phase 1 =  menstrual; Phase 2 =  postmenstrual; Phase 3 =  intermenstruai; Phase 4  = 
premenstrual.




Multivariate Analvsis of Variance for Famllv History of Mental Illness
(Mean Affect Scores)
Source df Error F
Between Subjects
Family History Group (FH) 2 89 0.16
Pill Group (PG) 4 180 0.89
FH X PG 4 180 1.81
Within Subjects
Cycle Phase (CP) 6 540 0.19
CP X FH 6 540 1.43
CPXPG 12 540 0.39
CP X FH X PG 12 540 1.20
Note. < .05. < ,01








Personal History Group (PH) 2 89 3 .5 8 *
PHI Group (PG) 4 180 1.07
PHXPG 4 180 1.59
Within Subjects
Cycle Phase (CP) 6 540 0.33
CPXPH 6 540 0.32
CPXPG 12 540 0.51
CP X PH X PG 12 540 1.16
Note. < .05. < .0 1 .




Analvsis of Variance for Personal History of Mental Illness 
(Mean Positive Affect Scores)
Source df F
Personal History Group (PH)
Between Subjects
1 0.01







CP X PH 3 0.01
CPXPG 6 0.38
CP X PH X PG 6 0.78
CP XS within- 
group error 270 (10.59)
Note. Values enclosed in parentheses represent mean square errors. 
S = subjects.
* £ < . 0 2 5 .  * * £ < . 0 1 .




Multivariate Analvsis of Variance for Personal Historv of Mental Illness
(Affect Variabilitv Scores)
Source df Error F
Between Subjects
Personal History Group (PH) 2 89 2.19
Pill Group (PG) 4 180 0.16
PHXPG 4 180 0.03
Within Subjects
Cycle Phase (CP) 6 540 2 . 5 7 *
CP X PH 6 540 0.24
CPXPG 12 540 1.37
CP X PH X PG 12 540 1.63
Note. *£  < .05. * *£  < . 0 1 .
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